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“The important thing in science is not so much to obtain new facts as to discover new ways of 
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The occurrence of HIV-1 superinfection suggests that infection with one strain of HIV-1 is not 
always protective against infection with a different strain. This has important implications for 
the design of an effective HIV vaccine. In this thesis we aimed to determine the timing and 
frequency of intra-subtype C superinfection, and to determine if the reason for superinfection 
was a greater genetic distance within epitopes of the superinfecting virus compared to those of 
circulating strains from the same cohort. 
Heteroduplex mobility assay was used together with sequencing and phylogenetic analysis of
the C2-C3 region of envelope to determine the frequency of superinfection in a cohort of high
risk women recruited during acute infection and followed for twelve months. Of the 19 women 
screened, two were found to be superinfected corresponding to an incidence of 10% per person
year (CAP237 and CAP256). A third individual with superinfection was identified through 
another project (CAP281) (R. Ntale pers. Comm.).  These individuals were superinfected at two, 
three and eleven months post primary infection respectively, with the date of superinfection 
calculated as midpoint between last detection of single infection and first detection of
superinfection. Superinfection was always associated with a greater than 0.5 log increase in
viral load.
The individuals identified as superinfected had significantly different disease profiles: CAP256
had a high viral load after primary infection (>100 000 copies /ml), and did not control viral
replication after superinfection (>750 000 copies/ml). In contrast the disease progression of
both CAP237 and CAP281 appeared to be unaffected by the second virus. CAP237 was a typical 
progressor with a viral load at set point of 10 000 copies per ml and CAP281 was a controller 














To compare potential CTL epitopes in initial virus compared to the superinfecting virus, we 
generated whole genome sequencing from two of the women, from time points before and after 
superinfection.  HLA restricted epitopes were mapped in both viruses to determine if epitope 
mismatch between the initial and superinfecting viruses may have resulted in lack of protection 
against superinfection.  The genetic distance between the initial and superinfecting viruses of 
CAP256 was substantially greater (6%) than that of the superinfecting and initial viruses of 
CAP281 (3%). For CAP256 there was a significant difference in coverage of the superinfecting 
virus by the initial virus when compared to other circulating CAPRISA sequences (p=<0.0001). 
When the HLA associated epitopes of the initial and superinfecting viruses were compared in 
both CAP256 and CAP281 putative escape mutations were detected in both superinfecting 
viruses, however this was more pronounced in CAP256.  It is proposed that sequence 
differences between the initial and superinfecting viruses in CAP256 may have resulted in an 
absence of immune recognition of the superinfecting virus and allowed superinfection to occur.  
Finally, the pattern of recombination in this virus was examined in CAP256 to determine if
recombination following superinfection could be driven by immune pressure. The recombinant
virus present at six months post infection in CAP256 was predominantly composed of the
superinfecting virus which was carrying several escape mutations. The regions where the
primary virus was incorporated were found to contain epitopes which carried escape
mutations. 
The results of this study have shown that superinfection is occurring frequently.  Unlike some 
previous studies, superinfection was not always associated with rapid disease progression. 
Finally, while the genetic distance between the primary and superinfecting strain may play a 
role in superinfection these signals were only detected in one of the two superinfected 
individuals examined.  Further work is needed to expand the numbers to get a more accurate 
estimation of frequency and timing of superinfection, and to complement this work with 
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In 2009, HIV infected more than 33 million people and caused 1.8 million AIDS-related deaths 
(114). The most effective approach to controlling this epidemic is through vaccination. One of 
the major challenges facing the development of an effective vaccine is the highly diverse global 
viral population comprising of 9 subtypes and 48 circulating recombinant forms (CRFs) (1). The 
HIV-1 epidemic is becoming increasingly heterogeneous (38) and this diversity is driven, in 
part, by recombination between different strains due to dual infection with two independent 
HIV strains (43, 49). Dual infection can occur through co-infection where an individual is 
infected with a second strain at or close to infection with the first virus; or superinfection when 
an HIV-1 seropositive individual becomes infected with a second HIV strain(49). 
The first cases of superinfection in humans were described in 2002 (5, 56, 86). Since then, more 
than 50 cases have been reported. It is not yet known what factors predispose individuals to 
superinfection but it has been proposed that high risk behaviour, the nature of the 
superinfecting virus, as well as the immune status of the host all play a role (16, 42, 118). 
Superinfection has implications on the development of an effective vaccine as it indicates that 
infection with one strain does not always protect against infection by a second strain. 
Consequently studies on superinfection may provide insight into the correlates of immune 
protection. Higher viral loads and faster disease progression have also been associated with its 
occurrence implying that it has pathogenic consequences for the individual (42, 50). 
The aim of this thesis is to identify cases of HIV-1 superinfection in the CAPRISA 002 cohort, and 
to ascertain whether genetic differences between the two strains allowed superinfection to 
occur. The thesis also aimed to determine whether CTL responses were a driving factor behind 

















1.1 HIV Diversity and Recombination 
 
HIV is a rapidly evolving virus due to: firstly the error prone nature of the reverse transcriptase 
which results in approximately one nucleotide substitution per genome per replication cycle 
(82); and secondly to recombination between two different RNA templates which are co-
packaged into each virion (129). In addition, substantial diversity is generated in a relatively 
short period of time due to the high viral turnover rate with an average generation time of 2.2 
days (77, 107). The generation time refers to the period of time between release of a new virion 
from an infected cell and it infecting a new cell and producing progeny virions(77). 
Recombination is much more efficient at introducing changes compared to point mutations as 
through recombination numerous changes can be introduced simultaneously. In addition, the 
rate of recombination in HIV is estimated to be 2.8 times per genome per viral replication cycle 
(129) compared to one nucleotide substitution per genome per replication cycle for point 
mutations (82). Thus, superinfection with two phylogenetically distinct viruses will potentially 
result in more rapid viral evolution compared to infection with a single virus. 




(Years) HIV Subtypes Risk Factor 
Time to Recombination 
after Superinfection 
(Years) 
Fang et al. (2004)(33) >6 C after A WSM >1 
McCutchan et al. 
(2005)(71) 0.5-0.75 AC after ACD recombinant WSM 0.25 
Pernas et al. (2006)(79) ~12 B after B IDU <1 
Piantadosi et al. 
(2007)(80) 4.6-5.6 A1 after D/A2 recombinant WSM Not reported 
Piantadosi et al. 
(2007)(80) 0.1 D after A WSM Not reported 
Piantadosi et al. 
(2007)(80) 5-5.4 C after A WSM Not reported 
Piantadosi et al. 
(2007)(80) 2-2.8 A after A WSM Not reported 
Piantadosi et al. 
(2007)(80) 0.8-4 A after A WSM Not reported 
Piantadosi et al. 
(2007)(80) 0.2-0.4 A after C/A recombinant WSM Not reported 
Streeck et al. 
(2008)(102) ~1.4 B after B Not reported 0.1 
Templeton et al. 
(2009)(108) 0-5 B after B IDU/WSM Not reported 
















The pathogenesis of HIV-1 may be extremely reliant on the virus’s ability to maintain its 
diversity as it provides a means for the virus to escape selective pressures such as host immune 
responses and antiretroviral therapy (27). It may also prove useful for escaping evolutionary 
bottlenecks during later stages of the disease thus preserving the longevity of the virus (27). 
While recombination is beneficial to pathogens enabling greater flexibility to respond to 
selective pressure, in dual infection it can also result in reduced diversity through the 
generation of a single recombinant strain. In an individual who was initially infected with an 
ACD recombinant virus and then became superinfected with an AC recombinant, there was 
initially an explosion of viral diversity with seven different molecular forms of the virus 
detected within three months of superinfection; however a recombinant form of the two 
infecting viruses became the dominant viral population later in infection (Table 1.1)(71). 
1.2 Frequency of Superinfection 
 
In regions where multiple HIV subtypes circulate, recombination between different subtypes 
can result in mosaic HIV genomes (24, 76, 103). Novel recombinant strains of the virus, 
generated by dual infection, are referred to as circulating recombinant forms (CRFs) and there 
are 48 which have been recorded. The high number of CRFs as well as Unique recombinant 
forms (URFs) in regions where two subtypes circulate suggests that co-infection and 
superinfection occurs frequently. Many attempts have been made to determine the frequency 
with which superinfection occurs and contrasting results have been reported with some studies 
finding high incidences while others were unable to detect superinfection at all (Table 1.2) (26, 
28, 50, 52, 54, 80, 97, 113, 128). 
Several studies have looked for the occurrence of dual infection in general without considering 
if the individuals are co- or superinfected. These studies are usually cross-sectional and have 
















(WSM) cohorts of high risk individuals in Africa. In Tanzania a cross sectional study examined 
600 female bar workers and found 19% of them to be dual infected (52). However, the 
shortcoming of this study was that analysis of a single time point post-infection could not 
distinguish whether the dual infections were co-infections or superinfections. 
More recently in order to distinguish between co- and superinfection longitudinal studies have 
been carried out, these studies are the only way to means of determining accurate incidences of 
superinfection. In Kenya the reported incidence of superinfection was 4.3% per person year 
when a cohort of 21 female bar workers was followed for five years post-infection (28) and 
3.7% of a cohort of 36 women over a period of six years (80).  A more recent study by 
Templeton et al. (2009) found 17% of a female cohort in the United States of America to be 
superinfected over a period of six years which is equivalent to an incidence of approximately 
2.8% per year (108). The results of these studies suggest high incidences of re-infection which 
are approaching the incidence of primary infection (Table 1.2). 
Table 1.2 Studies which have examined the frequency of HIV Re-infection 
Citation 








(per person year) Location 
Incidence of 
Primary Infection 
(per person year) 
Yerly et al. 2004(127) 156 Longitudinal IDU 0.57% Switzerland NA 
Chakraborty et al. 
2004(26) 
14* Longitudinal US/IDU 0% Spain NA 
Smith et al. 2004(99) 78 Longitudinal NA 5% USA ~5% 
Tsui et al. 2004(113) 37 Longitudinal IDU 0% USA ~0.02% 
Chohan et al. 2005(28) 21 Longitudinal WSM 4.3% Kenya 7.8% 
Herbinger et al. 
2006(52) 
600 Cross section WSM 19%# Tanzania 14% 
Piantadosi et al. 
2007(80) 
36 Longitudinal WSM 3.7% Kenya ~8% 
Sidat et al. 2008(97) 145 Longitudinal MSM 0.036% Australia NA 
Templeton et al. 
2009(108) 
58 Longitudinal IDU/WSM 2.8% USA NA 
Campbell et al. 2009(21) 8 Longitudinal MSM 0.03% USA NA 
Rachinger et al. 
2010(84) 
89 Longitudinal MSM 0% Netherlands 6.8% 
MSM, Men who have sex with men; WSM, Women who have sex with men; IDU, Intravenous Drug Users; US, Unprotected Sex 
*Couples not individuals 
















Compared to studies on women who have sex with men, lower frequencies of re-infection have 
been reported in cohorts of intravenous drug users (IDU). In the Netherlands an IDU cohort was 
found to have two superinfections out of the 156 individuals screened longitudinally, 
corresponding to an incidence of approximately 0.57% per person years (128). When 
intravenous drug users from San Francisco were screened for superinfection, 37 individuals 
were examined using samples which ranged from one to twelve years after initial infection and 
no dual infections were detected (112). 
Similarly, three men-who-have-sex-with men (MSM) cohorts followed longitudinally in 
Australia, USA and Netherlands had low incidence of superinfection, 0.036%, 0.03% and 0% 
respectively (21, 84, 97). The MSM cohort in the USA comprised of seroconcordant couples but 
after 71 months of longitudinal follow up, only two couples became superinfected (21). 
Furthermore, a cohort of 14 HIV seroconcordant couples were followed for four years all of 
whom were at high risk of re-exposure to the virus and no cases of superinfection were detected 
(26). Therefore, even though studies have indicated that the incidence of superinfection 
amongst WSM approaches that of primary HIV infection (Table 1.2), re-infection within 
seroconcordant couples is low even though they are also considered to be at high risk of re-
infection due to a number of factors such as unprotected sex and high viral loads. 
The chance of detecting superinfection is influenced by the risk of infection. In Tanzania they 
compared the incidence of dual infection in individuals at high risk to individuals with normal 
risk exposure and found the incidence in the second group to be much lower at 9% compared to 
the high risk group at 19% (52). Furthermore the lack of superinfection in a cohort of 89 
homosexual men in Amsterdam was attributed to a decrease in unsafe sexual behaviour (84). 
Several of the cohorts described in Table 1.2 comprise female sex workers with a high risk of 
infection, a likely factor driving the high incidence of primary infection which results in the 
















1.3 Timing of HIV Superinfection in Humans 
 
The timing of superinfection is important as it provides some clues as to the immune correlates 
of protection.  If, for example, it occurs predominantly in the first few weeks of infection then it 
is occurring before the development of any neutralizing antibody responses but in the presence 
of a developing CTL response. However in early infection, the CTL response is initially narrow, 
recognizing only a limited number of epitopes and thus probably has limited cross reactivity 
(48, 61). Neutralizing antibodies only develop after three months post infection and to begin 
with are predominantly autologous, recognising only their own virus (47, 87).  Neutralizing 
responses that recognise a diverse number of strains (broadly cross-neutralizing antibodies) 
usually only evolve two to three years following infection (47). Thus if superinfection occurs 
during the chronic stage of the disease, prior to the development of AIDS, then it is occurring in 
spite of relatively strong CD8+ T cell responses as well as neutralizing antibody responses. The 
AIDS stage of infection is associated with a compromised immune system making individuals 
more susceptible to opportunistic infections and thus infection with a second HIV-1 strain 
(34)(Figure 1.1). 
Cases of superinfection in humans have been reported to occur from the first month to more 
than twelve years after the initial infection (Table 1.3) (10, 25, 29, 79, 80). However, there have 
been a limited number of studies in large cohorts which have focused on the timing of 
superinfection. It was initially proposed that superinfection only occurred before host immune 
responses were fully developed (100), however with cases of superinfection being reported 
during the chronic phase of infection this does not seem to be the case (5, 16, 29, 56, 80). 
Piantadosi et al (2007) who identified seven cases of superinfection in a high risk cohort of 36 
women by longitudinal follow up for 5 years demonstrated that the timing of superinfection 
ranged from 53 days to 5 years after the initial infection. This illustrated that superinfection 
could occur at any stage of disease (80). Table 1.3 corroborates this finding as numerous studies 
















Table 1.3 Superinfection studies which have timed the occurrence of re-infection 
Citation 
Time to Superinfection 
(Years) HIV Subtypes Risk Factor 
Jost et al. (2002)(56) 2.4 B after A/E recombinant MSM 
Altfield et al. (2002)(5) 2.8 B after B IDU 
Ramos et al. (2002)(86) ~ 0.1 B after CRF01_AE IDU 
Ramos et al. (2002)(86) 1.25-1.7 CRF01_AE after B IDU 
Smith et al. (2004)(99) ~0.5 B after B NA 
van der Kuyl et al. (2005)(119) 1.3-1.6 B after B MSM 
van der Kuyl et al. (2005)(119) 2.3 CRF01_AE after B MSM 
Yang et al. (2005)(124) 0.4 B after B MSM 
Smith et al. (2005)(101) 0.7 B after B MSM 
Chohan et al. (2005)(28) 0.7-1.1 A after D WSM 
Chohan et al. (2005)(28) 0.8-1.6 C/A recombinant after C WSM 
Chohan et al. (2005)(28) 0.3-1.3 A after D WSM 
Pernas et al. (2006)(79) 12 B after B IDU 
Piantadosi et al. (2007)(80) 4.6-5.6 A1 after D/A2 recombinant WSM 
Piantadosi et al. (2007)(80) 0.1-0.2 D after A WSM 
Piantadosi et al. (2007)(80) 5-5.4 C after A WSM 
Piantadosi et al. (2007)(80) 2-2.8 A after A WSM 
Piantadosi et al. (2007)(80) 0.8-4 A after A WSM 
Piantadosi et al. (2007)(80) 0.2-0.4 A after C/A recombinant WSM 
Templeton et al. (2009)(108) 1-5 B after B IDU/WSM 
Clerc et al. (2010)(29) 6 CRF11_cpx after B IDU 
Clerc et al. (2010)(29) 3.6 CRF11_cpx after B IDU 
Braibant et al. (2010)(16) 10 B after B MSM 
MSM, Men who have sex with men; WSM, Women who have sex with men; IDU, Intravenous Drug Users 
Lack of large follow up studies over long periods of time and the wide range of differences in the 
timing (0.1-5.4 years) of reported cases of superinfection makes it difficult to predict when 
superinfection is most likely to occur. Viral and cellular kinetics may be one of the factors 
affecting the timing due to the availability of target cells. If the HIV-1 infected individual was 
exposed to a second virus in the later stages of infection after CD4+ T cells have been depleted 


















































Figure 1.1 The Natural History of HIV infection, depicting the viral load, CD4 cell numbers CD8 T cell and neutralising 
antibody responses over the course of infection (94)(Adapted from Sewell. 2000). 
It has been suggested that the early initiation of Highly Active Anti Retroviral therapy (HAART) 
may limit the HIV specific immune responses in HIV infected individuals due to lack of exposure 
to HIV-1 antigens (56). The waning immune responses may then allow superinfection of the 
individual. However ongoing use of antiretroviral therapy should prevent HIV superinfection if 
the superinfecting strain is still susceptible to that type of drug (40). 
1.4 HIV Diversity and Superinfection 
 
Some studies have shown that the genetic distance between the initial and the superinfecting 
virus affect the incidence of superinfection as responses to the first virus may not offer 
protection against the second virus due to mismatched epitopes (5, 86, 100, 124). This suggests 
that the greater the genetic diversity between the different strains the less likely that immune 
responses generated by the first virus will recognise and thus protect against re-infection. 
CD8+ T Cells 


















If immune responses play a role in the occurrence of superinfection then one would expect the 
risk of intersubtype superinfection (ie infection with strains from different subtypes that may 
differ by 30% at the amino acid level in the envelope gene) (63) to be greater than intrasubtype 
superinfection (ie infection with strains from the same subtype which may only differ by 10% 
or less at the amino acid level in the envelope gene) as immune responses would be more likely 
to protect against infection by related viruses from the same subtype that may share antigenic 
properties (20, 64, 88). However, comparing the incidence of intra and intersubtype 
superinfection is difficult as these studies ideally need to be done in cohorts where multiple 
subtypes are circulating. In addition, difficulties in detecting intrasubtype superinfection may 
influence the reported incidence as intersubtype superinfection is easier to detect (33). In 
Kenya, an area where multiple subtypes circulate, of the seven superinfections detected equal 
incidences of intra [4 cases] and intersubtype superinfections [3 cases] were found indicating 
that intrasubtype superinfections may occur just as readily as intersubtype superinfections 
(80). 
Several studies investigated whether HIV-2 infection prevented HIV-1 infection even though the 
sequence similarity was as low as 50% (74). One study in Senegal suggested that HIV-2 
infection was protective due to the lower incidence of HIV-1 infection in HIV-2 infected 
individuals compared to uninfected individuals (110). However, this was not supported by a 
later study in Guinea Bissau which showed that there was in fact a higher risk of HIV-1 infection 
after HIV-2 infection in all of the women in the study however this correlation did not extend to 
men (116). 
Further studies need to be carried out to determine whether a lack of cross recognition by host 
immune responses make individuals susceptible to re-infection by different subtypes as well as 
different types of HIV. These factors are of great importance in the design of an effective vaccine 


















1.5.1 Cellular Immune Response 
 
Knowledge of what controls primary infection will give us some clues on correlates of 
protection from superinfection. During primary HIV infection strong Human Leukocyte Antigen 
(HLA) class I mediated CD8+ Cytotoxic T Lymphocyte (CTL) responses are triggered (83, 121). 
These CTL immune responses have been shown to play a role in the control of HIV replication 
(14, 41, 45, 46, 61). A very select number of individuals (viremic controllers with viral loads 50< 
and >2000 RNA copies/ml and elite controllers with viral loads below 50 RNA copies/ml) are 
able to exhibit almost complete control over viral replication (6, 78) usually due to persistent 
gag CTL responses. The loss of these gag responses has been associated with progression to 
AIDS (39, 60, 78, 91). 
During the course of infection host immune pressures select for changes in CTL epitopes 
thereby enabling viral escape from CTL responses (7, 18, 31). CTL escape mutations can have 
two outcomes: 1) loss of control of viral replication and progression to AIDS (45) or 2) the 
escape mutations impact protein funct on thereby reducing viral replicative capacity leading to 
delayed disease progression (8, 13, 18, 18, 31). Escape from three immune-dominant HLA 
B*57/B*5801 associated ep topes located on the HIV-1 capsid was recently shown to come with 
a fitness cost as viruses carrying these CTL escape mutations had significantly reduced 
replicative capacity. The accumulation of additional escape mutations in the epitope reduced 
viral fitness further and the authors suggest that this likely impacts in vivo replication of the 
virus (15)(68). 
Infection with one subtype was may be able to elicit CTL responses protective against a variety 
of subtypes, although intrasubtype CTL recognition is generally stronger than recognition of 
viruses of different subtypes (9, 22, 23). However, the mere existence of HIV superinfection 
















have reported an absence of CTL recognition of the superinfecting strain (5, 102, 124). One of 
the first cases of superinfection was associated with an absence of CD8+ T cell responses to 
seven of the 25 previously recognised epitopes. This lack of response was due to sequence 
differences between the two viruses which differed by 12% at the amino acid level. However, 
eight epitopes were conserved in both viruses suggesting some degree of cross-recognition 
occurred although this was insufficient for protection (5). In a similar study a patient with an 
established cytotoxic T lymphocyte (CTL) response effectively controlling his primary infection 
was unable to protect against superinfection even though the CTL response was broad and 
stable. On further examination of their CD8 T cell responses it appeared that subsequent to 
superinfection the initial responses were reduced and there was some targeting of novel 
epitopes. The loss of initial responses was contributed to differences in sequence of the 
recognized epitopes in the superinfecting virus which subsequently outgrew the initial strain 
(124). It is evident from these studies that the specificity of the initial CTL immune response is 
unable to recognize and respond to the superinfecting strain due to significant differences in 
their sequences (5, 124). 
Superinfection has been proposed to increase the rate at which CTL escape occurs through 
recombination. A study found that an individual who was effectively controlling his virus, lost 
control following superinfection (102). Examination of the gag and env genes showed that this 
loss of immune control coincided with recombination events in two immunodominant CD8 
epitopes in these two genes. The recombination events in these epitopes (B27-KK10 in Gag and 
Cw1-CL9 in Envelope) rapidly facilitated escape from both dominant wild type-specific and 
variant-specific responses. Novel CD8+ T cell responses were then detected in these two regions 
of recombination which replaced the initial responses present before superinfection suggesting 
that cellular immune pressure may have played a role in driving recombination in this 

















1.5.2 The Humoral Immune Response 
 
The first anti-HIV antibodies are seen within the first week of infection and comprise of binding 
antibodies (109) followed by the production of autologous neutralising antibodies between 12 
and 20 weeks after infection (47, 66). These early neutralising antibodies are usually specific to 
the infecting virus; however from around two years post infection these responses may broaden 
and recognise other variants as well (cross-neutralizing responses)(47, 72, 87, 122). 
One of the first studies to look at the neutralising antibody responses in superinfected 
individuals found that, of the 14 individuals with superinfection, 3 were superinfected between 
0 and 6 months post infection. A correlation was observed between the level of cross 
neutralizing antibodies and superinfection as individuals who became superinfected had lower 
titres of cross-protective neutralizing antibodies before superinfection than those who did not 
become superinfected. Furthermore, the antibodies of the non-superinfected individuals were 
also able to neutralise more HIV variants than those of the superinfected individuals (100). 
Ramos et al. (2002) investigated two intravenous drug users, who even though they had mature 
humoral immune responses to their initial viruses became superinfected with different viral 
subtypes due to limited cross-recognition (86). These studies suggest that broadly cross-
reactive antibodies may play a role in protection from superinfection. 
Conversely, it has recently been suggested that a diminished neutralizing antibody response is 
not responsible for the occurrence of superinfection. The neutralising antibody responses of six 
women who had become superinfected between one and five years post infection were 
compared to 18 women who were at a similar risk of re-infection and who did not become 
superinfected. There were no significant differences in the breadth or potency of responses 
prior to superinfection between the superinfected women and the control group. It was also 
















neutralising antibody response against the second virus (11). Further studies are needed to 
elucidate the role of neutralizing antibodies in the preventing superinfection. 
1.6 Animal Models 
 
Animal models have been used to evaluate the correlates of protection from superinfection.  
Although these studies have yielded conflicting results due to differences in study design, 
methods of inoculation, animal models, as well as the viral strains, they nevertheless do provide 
some insights into understanding correlates of protection. 
Early studies demonstrated that Chimpanzees could be re-infected by an HIV stain from a 
different subtype six months after infection with the first strain (36).  However, using different 
viruses and much higher infectious doses a later study showed that chimpanzees which had 
been infected with HIV-1 for between 22 and 101 months were resistant to repeated and 
escalating inoculations of a heterologous intraclade strain of the virus (96). In the Simian 
Immunodeficiency Virus (SIV) Rhesus macaque model, a recent study showed infection with 
one strain of SIV did not protect against re-infection with a heterologous SIV challenge as 12 out 
of the 14 monkeys became superinfected. The timing of superinfection in the monkeys ranged 
from three to 20 months post infection. However this study also showed that the monkeys were 
able to control the replication of the second virus more efficiently than they controlled the first 
virus. When they compared the immune parameters of the twelve animals that became 
superinfected to the two animals that did not, they found that neither the CD4+ T-cell numbers, 
CD4+ memory T cell subsets, cytokine production by virus specific CD8+ T cells, nor 
neutralizing antibodies were associated with control of the second virus (126). However they 
found that the two SIV-infected macaques had protective HLA alleles and despite the challenge 
viruses containing CTL escape mutations in epitopes associated with these HLAs, they remained 

















These studies suggest that superinfection is possible in most animal models however further 
studies are required to determine whether any protection is provided by the first infection 
against re-infection and what immune parameters are associated with this protection. 
1.7 Detecting HIV superinfection 
 
Superinfection can be difficult to detect which may have some bearing on differences in 
reported incidences. Many methods have been explored including the heteroduplex mobility 
assay, the multi-region hybridization assay, restriction fragment length polymorphism and the 
use of ambiguity codes present in population based sequences (28, 30, 53, 84, 118). Most of the 
methods are time consuming and accurate detection of superinfection requires longitudinal 
follow up (28, 30). As several cases of superinfection have been accompanied by increases in 
viral load, as well as changes in drug resistance profiles, these parameters can also be used to 
identify individuals with possible superinfection (17, 33, 44, 71, 99, 124). However,  there have 
been cases of superinfection where viral load does not increase, and therefore superinfection 
may be missed if this is used as the sole means of screening for its occurrence (80, 100). 
Recombinant viral populations are also often used to infer the occurrence of HIV-1 
superinfection as they can only be generated as a result of a dual infection (105) however 
recombination between the initial and superinfecting strains can also prevent detection of 
superinfection if only a single region of the genome is studied (80)(81). 
In an individual infected with multiple viral variants the ratio of the infecting viruses fluctuates 
(50). The proportion of the multiple viral populations infecting an individual can conceal the 
occurrence of superinfection because if the superinfecting virus is a minor population then it 
may not be detected (71). Similarly, in some individuals the initial virus is lost through 
competition with the superinfecting virus (28, 80, 108, 120) which may result in the presence of 
















(33, 118). It would thus appear that even if superinfection occurred frequently, the difficulty to 
detect the viral populations may lead to an underestimation of its incidence. 
1.8 The Nature of the Superinfecting Virus 
 
The susceptibility of host immune cells to reinfection, particularly CD4+ T cells, is a critical rate 
limiting feature of superinfection. Susceptibility is a measure of the viral and cellular factors 
which make an infected cell resistant to re-infection. If less target cells are susceptible to re-
infection then competition between viral strains will result in the exclusion of one of the viruses. 
Conversely if there are many cells susceptible to re-infection then co-existence of the two 
viruses may occur particularly if the viruses are of equal fitness (37) 
The fitness of the infecting viruses also impacts the dominance of viral populations due to 
competition for target cells. Low replicative fitness of the first virus has been associated with 
superinfection and it was suggested that individuals infected with poorly replicating variants 
have higher CD4 counts, making target cells available to the superinfecting strain (16, 17, 62, 99, 
100, 115). However, superinfection has also been shown to occur when both initial and 
superinfecting viruses are of equal fitness (28, 101, 124). This suggests that although in some 
cases initial infection with a weaker virus may make the individual more at risk of 
superinfection fitness is only one possible factor which may influence their susceptibility. 
1.9 Pathogenic Consequences of HIV Superinfection 
 
Superinfection can impact an individual in a number of ways, either by accelerating disease 
progression or through the generation of multi-drug resistant strains (50, 71, 79). 
There are several studies which have shown that superinfection has been associated with 
increased viral load and faster disease progression (16, 42, 50, 62). One study found that 
















superinfected individuals who usually only progress to AIDS within 8 to 10 years (42). Similarly, 
superinfection of an HLA-B57+ long term non-progressor resulted in an increase in viral load 
and a corresponding decline in CD4+ cell numbers (16). However superinfection is not always 
associated with accelerated disease progression. In two long term non-progressors it appeared 
that their immune responses were able to control the superinfecting strain such that there was 
no acceleration of disease progression (25). The potential for superinfection to rapidly increase 
the diversity within an infected individual has consequences for the individual with respect to 
their disease profile as well as their immune responses.  
1.10 Study Rationale and Specific Objectives 
 
A vaccine remains our best hope in controlling the HIV-1 epidemic.  Studies on superinfection 
may provide a better insight into what immune correlates of protection are required for an 
effective vaccine. This study investigates superinfection in a cohort of high risk women from 
KwaZulu-Natal to determine the incidence and timing of superinfection, and to ascertain 
whether genetic differences between the two strains were responsible for the occurrence of 
superinfection. In particular differences in Cytotoxic T cell epitopes between the initial and 
superinfecting viruses will be examined to determine whether the inability to recognise 
epitopes on the superinfecting strain is a determinant of superinfection. Furthermore, this study 
will also determine the role of recombination between the initial and superinfecting viruses in 
selecting specific CTL epitopes that confers escape from the immune system. 
The research performed is part of the Centre for AIDS Program of Research in South Africa 
(CAPRISA) 002 study. 
The main objectives of this research project were: 
 To determine the frequency of HIV-1 superinfection over the first year of infection in the 
















 To characterize the evolution of the initial and superinfecting strains within the full 
length genome of two superinfected individuals. 
 To establish whether genetic differences between the two strains may have prevented 
recognition by the host immune system. 
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Superinfection has implications for the development of effective vaccine strategies as it 
provides evidence that infection with one strain of HIV does not protect against a second 
infection (28, 80). It also has public health considerations as superinfection has been linked to 
faster disease progression (16, 42). If the incidence of superinfection approaches that of 
primary HIV infection, as was previously found in the study in Kenya, this implies that little or 
no protection is provided by the first infection (80).  
Several methods have been used to determine the frequency of superinfection however 
differences in sensitivity of detection, study design, cohorts, circulating subtypes, and stage of 
infection have contributed to inconsistent findings (28, 30, 118). Some of the methods used to 
detect HIV-1 superinfection include restriction fragment length polymorphism (RFLP) (55), 
heteroduplex mobility assay (HMA) (67), multiregion hybridization assay (MHA) (53) and 
population based sequencing to determine the number of degenerate base codes (30). The RFLP 
and MHA methods can detect inter-subtype dual infections, whereas the HMA and population 
based sequencing method are able to discriminate between both inter and intra-subtype dual 
infections. 
Subtype C is responsible for over 95% of infections in South Africa and we were therefore 
interested in a method that could identify intra-subtype superinfection. Population based 
sequencing uses the number of degenerate base codes detected during sequencing as an 
indicator of multiple viral populations where the presence of 45 or more degenerate base codes 
within reverse transcriptase (~ 1320 bp) were shown to correctly identify 73% of dual infected 
individuals (30). The heteroduplex mobility assay is based on the principle that heteroduplexes 
are formed when partially complementary DNA strands are denatured then allowed to re-
anneal. The extent of variation in sequence can then be derived from the reduced 
















distortions resulting from mismatched and unpaired nucleotides (32). The sensitivity of this 
assay allows the detection of viruses that differ by 0.86% in the C2-C3 region of envelope (50). 
The HMA was found to be more sensitive than the genotyping method suggesting it is the ideal 
method for detecting intra-subtype superinfection (84), thus this method was selected for our 
study. 
One of the criteria used to target individuals for superinfection screening is an unexpected 
increase in viral load which often accompanies superinfection with a second strain (44, 71, 
100). However, as an increase in viral load is not always present (57), using this as a screening 
tool may result in superinfection being missed. In addition, it is also important for longitudinal 
follow up as fluctuating viral populations and recombination may also result in superinfection 
not being detected (28, 30).  In this study we therefore screened all participants for 
superinfection, over four time points within the first year of infection. 
The CAPRISA 002 cohort recruited participants during acute infection and has followed them 
over time to assess virological and immunological factors impacting disease progression. The 
cohort is based in Kwa-Zulu Natal and consists primarily of high-risk women with a mean age of 
34.3 years (range 18 to 58). The prevalence of HIV within the screening population was 
exceptionally high at 59.6% and the sero-incidence within the cohort was 7.2% per 100 person 
years (117). This cohort provides a means of determining the frequency of HIV superinfection 
as, despite extensive counselling, many of the HIV positive women continued to engage in high 
risk behaviour which provides the opportunity for re-infection (117).   
In this chapter we aimed to determine the frequency of superinfection in 20 participants in the 
CAPRISA 002 cohort within 12 months post-infection. We used HMA of the C2-C3 region of 
envelope together with sequencing and phylogenetic analysis to detect cases of HIV 





















The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 Acute Infection 
Study is a natural history study of subtype C HIV infection. It monitored HIV negative high-risk 
individuals monthly (117) who are screened for HIV infection using PCR (Determine; Abbott 
Laboratories, Tokyo, Japan) and two rapid antibody tests. It also recruited from individuals in 
rural areas of KwaZulu Natal who were participating in prevention research. On obtaining a 
negative antibody test the individual was enrolled in the HIV-negative cohort however if it was 
positive a second rapid antibody test (Capillus; Trinity Biotech, Jamestown, NY, USA) was 
administered. The time of infection was taken to be either the midpoint between the first 
antibody positive test and the last HIV-1 negative test or as the first 14 days when individuals 
are PCR positive and antibody negative. On enrolment individuals had their CD4+ T cell counts 
and viral load monitored on a weekly basis for the first month, then monthly until a year post-
infection and quarterly thereafter. Viral loads were measured using a COBAS AMPLICORTM HIV-
1 Monitor Test v1.5 (Roche Diagnostics, Basel Switzerland) and CD4+ T cell counts were 
measured using a FACSCalibur flow cytometer. Plasma was collected from each individual in 
EDTA and stored at -70°C. The clinical data was provided by K. Mlisana (University of KwaZulu-
Natal, South Africa). Ethics approval was given by the research ethics committees of the 
University of Kwa-Zulu Natal (E013/04), the University of Cape Town (025/2004) and the 
University of the Witwatersrand (MM040202). 


















2.2.2 RNA Extraction 
 
Viral RNA was extracted from 200 ul aliquots of plasma using the MagnaPure RNA Isolation Kit 
(Roche) and the MagnaPure Compact Nucleic Extractor (Roche). RNA was stored at -80°C. 
2.2.3 Reverse Transcription 
 
To generate cDNA the Promega Reverse Transcription Kit (Promega, Madison USA) was used. 
RNA (4 ul) was added to the Env N (0.2 uM) primer (Table 1) and incubated at 65°C for 5 
minutes before adding Buffer (1X), RNasin (20 units), MgCl2 (3.75 mM), deoxyribonucleoside 
triphosphates (dNTPS) (0.5 mM of each dNTP), reverse transcriptase (1 ul) and DEPC- treated 
water to a total volume of 15 ul. The reaction was carried out by heating to 25°C for 5 minutes, 
followed by 42°C for 1 hour and then 70°C for 15 minutes using the Applied Biosystems 2720 
Thermal Cycler (Applied Biosystems, Carlsbad, CA USA). 
2.2.4 PCR Amplification of C2-C3 region of the Envelope gene 
 
A nested population PCR amplification protocol was followed for amplification of the C2-C3 
envelope fragment. The first round reaction consisted of dNTPs (0.2 mM each)(Invitrogen, 
Carlsbad USA), 1X Buffer B (Kapabiosystems, Cape Town South Africa), the ED33 primer (0.2 
uM)(Integrated DNA Technologies, Coralville USA), the ED31 primer (0.2 uM)(Integrated DNA 
Technologies, Coralville USA), 1 unit of Kapataq polymerase (Kapabiosystems, Cape Town South 
Africa) and 5 ul of the template cDNA. The cycling profile consisted of an initial denaturation 
step at 94°C for 2 minutes, followed by 35 cycles of denaturation at 94°C for 15 seconds, 
annealing at 50°C for 45 seconds and elongation at 72°C for 1 minute. The second round 
reaction or the inner reaction consisted of dNTPs (0.2 mM each), 1X Buffer B, the BF primer (0.2 
uM)(Integrated DNA Technologies, Coralville USA), the BR primer (0.2 uM)(Integrated DNA 
Technologies, Coralville USA), 1 unit of the Kapataq polymerase, 5 ul of the product of the first 
















profile used was the similar to that used for the first reaction except that 45 cycles of 
amplification were used and the annealing temperature was increased to 55°C to increase the 
specificity of the amplification. All amplifications were carried out on the Applied Biosystems 
2720 Thermal Cycler (Applied Biosystems, Carlsbad, CA USA). 
Table 2.1: PCR Primers used for Amplification of C2-C3 
Name Sequence HXB2 Position Forward/Reverse 
EnvN 5’- CTGCCAATCAGGGAAGTAGCCTTGTGT 60-86 Reverse 
ED31 5’-CCTCAGCCATTACAGGCCTGTCCAAAG 7359-7380 Forward 
ED33 5’-TTACAGTAGAAAAATTCCCCTC 6816-6844 Reverse 
envBF 5’-TAACACAAGCCTGTCCAAAGG 6826-6847 Forward 
envBR 5’-AATTCTAGGTCCCCTCCTGA 7317-7337 Reverse 
 
2.2.5 Agarose Gel Electrophoresis 
 
To check the amplification of the C2-C3 region (~500 bp),PCR products were separated on a 1% 
agarose gel made up in Tris Borate EDTA (TBE) (Appendix C5) with a molecular weight marker 
(100bp DNA ladder Plus; Promega, Madison USA). Loading dye (Appendix C3) containing Gel 
Red (Biotum, Hayward USA) was added to each sample.  The gel was then visualized using ultra 
violet light (UVIpro Silver; UVItec, Cambridge United Kingdom). 
2.2.6 Heteroduplex Mobility Assay (HMA) 
 
HMA was used to screen individuals for HIV superinfection (32). 
In order to identify the presence of more than one variant at each time point the C2-C3 PCR 
product was heat denatured at 94°C  for 2 minutes and allowed to anneal at ambient 
temperature. To determine whether there were differences in quasispecies between time points 
the PCR product from two different time points were combined before denaturing and re-
















To check for heteroduplex formation samples were run on a polyacrylamide gel (5%)(Appendix 
C) at 250 volts for 150 minutes using the Scie-Plas V20 vertical gel apparatus with glass plates 
20cm x 19.5cm and spacers 1.5mm thick were used (Scie-Plas Ltd, Southam Warwickshire 
England). Once the gel had run to completion it was stained with Ethidium Bromide for 5 
minutes and then viewed using the UVIpro Silver UV box (UVItec, Cambridge United Kingdom). 
A positive control, included with each experiment comprised of enrolment samples amplified 
from two different CAPRISA individuals which were combined before denaturing and annealing. 
2.2.7 Sequencing of C2-C3 PCR Product 
 
To confirm the presence of different variants the C2-C3 PCR product was sequenced using the 
second round primers envBF and envBR. To clean up the PCR product and remove any 
components which could produce unwanted background in the sequencing results, the PCR 
product was treated with Exosap (1 unit)(USB, Cleveland USA) and placed at 37°C for 15 
minutes followed by inactivation at 80°C for 15 minutes. For each individual sample two 
sequencing reactions were performed using the ABI PRISM dye terminator cycle-sequencing kit 
(Applied Biosystems, Carlsbad, CA USA) The sequencing reaction of buffer, the forward or the 
reverse primer (0.1 pM) and distilled water to a total volume of 20 ul were placed in a 0.25 ml 
PCR tube. The cycling conditions included an initial denaturation at 96°C for 5 minutes, followed 
by 25 cycles of denaturation at 96°C for 30 seconds, annealing at 50°C for 15 seconds and 
elongation at 60°C for 4 minutes. The sequencing reactions were sent to the Stellenbosch 
University DNA Sequencing Unit to be run on their genetic analyzer. 
2.2.8 Sequence analysis 
 
The sequences were assembled using ChromasPro Version 1.42 (Technelysium, Australia), the 
resulting contigs were then aligned using Bioedit Sequence Alignment Editor Version 7.0.9.0 
(51). The alignment files were then imported into Mega version 4.0 (104) to generate the 
















used to draw the phylogenetic trees, this method is based on the principal that the taxon are 
paired such that the smallest total branch length is generated in the phylogenetic tree (93). 
Sequence alignment files for each individual, containing the sequences for each of the time 
points amplified, were uploaded into the Highlighter tool on the Los Alamos HIV Sequence 
Database (www.hiv.lanl.gov). The function of this tool is to highlight any mismatches, matches, 
transition and transversion mutations as well as silent and non-silent mutations in a set of 
aligned sequences which are in frame.  
2.2.9 Graphs 
 
The pairwise DNA distances of the individuals screened were plotted on graphs using GraphPad 
Prism 4.0 (GraphPad Software Inc. USA).  
2.3 Results 
 
To identify superinfection, the C2-C3 region of envelope was amplified in 20 individuals using 
plasma samples from enrolment (acute HIV infection), three, six and twelve months post 
infection. Of these 20 individuals 17 were screened for superinfection using the HMA, 
sequencing and phylogenetic analysis. The remaining three individuals were screened using 
only sequencing and phylogenetic analysis. All 20 individuals were infected with subtype C HIV 
throughout envelope as shown by M. Abrahams (2).  
The median log viral load and CD4+ count for these individuals at twelve months post infection 
was 4.77 copies/ml (range= 2.66 - 6.09 copies/ml) and 351 cells/ul (range= 202 – 1016 
cells/ul) respectively. Out of the 20 individuals screened 8 had a spike in viral load of greater 
than 0.5 log after acute infection and within the first year of infection (CAP65, CAP210, CAP228, 

















Figure 2.1 Viral Load Profiles of Individuals exhibiting a spike in viral load greater than 0.5 log, A) CAP65, B)CAP210, 
C) CAP228, D) CAP237, E) CAP239, F) CAP256, G) CAP258 and H) CAP281. The green arrows indicate the peaks in 
viral load and the blue arrows in the superinfected individuals indicate the timing of superinfection.  
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2.3.1 Viral Diversity  
 
HMA was used to screen for diversity within a time point.  In addition, each time point was also 
mixed with every other time point from that individual to determine if there was replacement of 
one strain with a second strain.  The method had previously been used in this laboratory to 
screen for intrasubtype dual infection and was found to differentiate C2-C3 amplicons with a 
distance greater than 0.86% (50).  The C2-C3 env region was selected as this region is variable 
enough to distinguish between different strains from the same subtype but contains the least 
number of insertions and deletions of all of the variable regions within envelope. It is important 
to have few insertions and deletions and they affect the migration of the DNA and thus may 
produce a false positive. 
Three patterns of evolution were detected using HMA, together with sequencing:  (i) women 
infected with a homogeneous viral population with no or limited diversification up to 12 
months post infection, ii) women infected with a heterogeneous virus population that continued 
to evolve over time and iii) women infected with a homogenous viral population with evidence 
of other variants post infection. 
Women infected with a homogenous viral population with no or limited diversification up to 12 
months post infection 
Thirteen women were identified to have a homogenous viral population with no or limited 
diversification over the first year of infection (CAP30, CAP61, CAP63, CAP65, CAP129, CAP174, 
CAP206, CAP210, CAP239, CAP244, CAP255, CAP257, CAP258).  This is illustrated by the HMA 
of CAP30 which shows a discrete band at enrolment and the following time point indicative of a 
homogeneous viral population and when time points were mixed no heteroduplex bands were 
detected (Figure 2.2A). These results are reflected in the phylogenetic tree and highlighter plot 
(Figure 2.2B), which show that there is a gradual accumulation of mutations over time. 
















months post infection was 0.014%. These results explain the absence of any heteroduplex 
bands as the assay is only able to pick up diversity greater than 0.86% (50). 
Women infected with heterogeneous viral population which continued to evolve over the first year 
of infection 
Four individuals were found to be infected with multiple variants which continued to diversify 
over the first year of infection (CAP69, CAP177, CAP222, CAP228). HMA analysis of CAP69 
exhibited faint heteroduplexes at enrolment demonstrating that the individual was infected 
with highly diverse variants. In addition at twelve months post-infection (lane 6)(Figure 2.2C) 
the multiple heteroduplex bands were indistinct due to smearing. Smearing has been associated 
with a diverse quasispecies (50) suggesting that the variants transmitted to CAP69 continued to 
evolve over the course of infection. The highlighter plot indicated a number of mismatches 
between sequences from enrolment and three months post-infection (Figure 2.2D). These 
results suggest that one variant became dominant at three months and was then replaced by 
another virus at six months which then persisted. In support of these results individual CAP69 
had been previously shown to be infected with five variants at transmission based on envelope 
single genome amplification with a maximum DNA distance in envelope of 3.5%(2) and 7.9 % 


















Figure 2.2 HMA screening and phylogenetic analysis of CAP30 and CAP69 at enrolment, 3, 6 and 12 months post-
infection with a and b indicating duplicate PCR reactions. A) CAP30 HMA, B) CAP30 Neighbor-joining tree and a 
highlighter plot of the C2-C3 region of envelope. C) CAP69 HMA. D) CAP69 Neighbor-joining tree and a highlighter 
plot of the C2-C3 region of envelope. The colors in the highlighter plot represent changes to: A = Green, T = Red, G = 
Orange, C = Light Blue, IUPAC = Dark Blue and Gaps = Grey. 
Women infected with homogeneous viral population with evidence of other variants post infection 
Two women (CAP237 and CAP256) were identified as potentially superinfected using HMA, 
sequencing and phylogenetic analysis. These women were initially infected with a homogenous 



















A single homogeneous population was detected at enrolment. The faint bands visible at 
enrolment (Fig 2.3A lane 2) co-migrated with the molecular weight marker and were thought to 
be due to overflow from the adjacent lane (lane 1).  A slow migrating band was visualized at 
three months post infection, suggesting that multiple strains were present at this time point. 
When the enrolment and 3 months post-infection sample were mixed a new band was 
visualized with reduced mobility, suggesting a second virus infected the individual after 
enrolment. A similar banding pattern was observed when the enrolment sample was mixed 
with amplicons from six and twelve months post-infection (lanes 9 and 10) (Figure 2.3A), 
suggesting that the second virus that appeared at 3 months persisted at later time points. The 
twelve month sample (lane 6) contains a prominent homoduplex, suggesting that there was low 
diversity at 12 months post-infection. Population PCR followed by sequencing shows a high 
number of mismatches between the population sequences at enrolment and three months post 
infection (Figure 2.3B). Sequences at six and twelve months post-infection grouped with the 
three months post infection sequence supporting the HMA data that the variant that appeared 

















Figure 2.3 HMA screening and phylogenetic analysis of CAP237 A) HMA at enrolment, 3, 6 and 12 months post-
infection with a and b indicating duplicate PCR reactions. B) Neighbor-joining tree and a highlighter plot of the C2-C3 
region of envelope. The blue stars in the heteroduplex mobility assay indicate those lanes where heteroduplex bands 
were observed. The colors in the highlighter plot represent changes to: A = Green, T = Red, G = Orange, C = Light Blue, 
IUPAC = Dark Blue and Gaps = Grey. The six month sample and the mixed enrolment and one of the 3 months samples 
(lane 5 and 8) did not yield bands most likely due to pipetting error. 
CAP256 
For CAP256, a homogeneous population was found at enrolment with faint slow migrating 
bands visualized at four months post infection (Figure 2.4A). No heteroduplexes were present at 
six months post infection. Slow migrating heteroduplex bands indicative of intrasubtype dual 
















three months post infection (lanes 10 to 13). There was also a heteroduplex band present when 
the PCR product from three months post infection was mixed with those from both four (lanes 
14 and 15) and  six months post infection (lanes 16 and 17), suggesting that the viral 
populations differed between these time points. The presence of multiple heteroduplex bands 
suggests that the individual was infected with multiple viral populations. Overall, HMA data 
suggests that CAP256 became infected with a second virus between enrolment and 4 months 
post-infection. The phylogenetic analysis of CAP256 supported the results of the heteroduplex 
mobility assay. The neighbor-joining tree suggests that the virus present at three months post-
infection is identical to the transmitted variant and that these two viruses were different from 

















Figure 2.4 HMA screening and phylogenetic analysis of CAP256 A) HMA at enrolment, 3, 6 and 12 months post-
infection with a and b indicating duplicate PCR reactions. B) Neighbor-joining tree and a highlighter plot of the C2-C3 
region of envelope. The pink stars in the heteroduplex mobility assay indicate those lanes where heteroduplex bands 
were observed. The colors in the highlighter plot represent changes to: A = Green, T = Red, G = Orange, C = Light Blue, 
IUPAC = Dark Blue and Gaps = Grey. 
2.3.2 Phylogenetic analysis of the individuals infected with homogeneous viral populations with 
evidence of other variants post infection  
 
To determine if these individuals were superinfected with epidemiologically unlinked viruses, 
we compared the C2-C3 region of envelope from each individual over time (Figure 2.5). In 
addition to CAP256 and CAP237, CAP281 was included in this study after R. Ntale (University of 
















analysis of the gag region. As this individual had already been identified as a putative 
superinfection, she was not screened using HMA.  
The individuals identified to be infected with homogeneous viral populations (n=13) had 
sequences over time which either exhibited low diversity with no structure on the phylogenetic 
tree or showed some structure in the tree over the first year of infection. Of the thirteen 
individuals identified as having been infected with homogenous viral populations in the HMA, 
two individuals (CAP61 and CAP244) had no evidence of diversification in C2-C3, while eleven 
individuals (CAP30, CAP63, CAP65, CAP129, CAP174, CAP206, CAP210, CAP239, CAP255, 
CAP257 and CAP258) exhibited some diversification.   The sequences from those individuals 
that had heteroduplex banding patterns at enrolment on HMA clustered together with a high 
DNA distance (CAP69, CAP177, CAP222 and CAP228). The sequences of the three individuals 
with putative superinfection separated from one another by other epidemiologically unlinked 
viruses (superinfected individuals)(CAP237, CAP256 and CAP281)(Figure 2.5). The composite 
phylogenetic tree was therefore able to confirm the results of the screening. 
Timing of Superinfection 
 
The sequences from CAP256 separated into two clusters; enrolment and three months on one 
branch and four, six and twelve months on another.  These sequences were separated on the 
tree by epidemiologically unlinked sequences confirming superinfection between three and four 
months post infection (Figure 2.5). The sequences of CAP237 generated at and after three 
months post infection clustered on a different branch to that of the enrolment sequence 
indicating superinfection between enrolment and three months post infection (Figure 2.5). For 
CAP281 one branch of the phylogenetic tree contained sequences from enrolment as well as 
time points leading up to and including ten months post infection, while the eleven months post 
infection sequence was located on a different branch of the tree, separated by an 
















post infection. These results were supported by Gag sequences generated by R. Ntale. For 
CAP237 and CAP256 although both the HMA and phylogenetic analysis support the occurrence 
of superinfection in these individuals strain specific was used to confirm the timing  of 
superinfection (D. Sheward and R. Ntale, University of Cape Town. Pers. Comm). 
Of the initial nineteen samples screened by HMA, two were confirmed as superinfected (10.5%) 
(Appendix A2). A third individual (CAP281), not included in the initial screen, was identified as 
superinfected through population sequencing of gag.  It was interesting to note that the three 
individuals identified as superinfected were included in the eight individuals identified as 

















Figure 2.5 Neighbor-joining phylogenetic tree of longitudinal (enrolment to 12 months post infection) envelope 
C2C3 sequences. The tree includes sequences from CAPRISA individuals, both the individuals screened in this study 
and sequences generated by Z. Woodman and M. Abrahams, as well as reference sequences obtained from the Los 
Alamos HIV-1 Sequence Database (www.hiv.lanl.gov). The sequences from the individuals screened in this study are 
indicated by the green circles for homogenous transmission, the blue circles for heterogeneous transmission and the 
pink circles for superinfected individuals. The black triangles indicate sequences generated by Z. Woodman 
(University of Cape Town) and M. Abrahams (University of Cape Town). The branch nodes without any markers 
indicate those sequences obtained from the Los Alamos HIV-1 Sequence Database. The phylogenetic tree was 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.3 DNA Distance as a indicator of Superinfection 
 
We next wanted to determine whether the pairwise DNA distance over the first year of infection 
could be used as a means of detecting superinfection, whereby superinfected individuals would 
have a substantially higher DNA distance than non-superinfected individuals. The pairwise DNA 
distance between the envelope C2-C3 viral sequences for each individual at enrolment and at 
twelve months post infection was measured (Figure 2.6) to determine the difference between 
the viral populations. The three individuals who became superinfected had the greatest DNA 
distance with the highest seen in CAP281 (18.1%), followed by CAP237 (11.2%) and the lowest 
observed in CAP256 (7.1%) over the first year of infection. The observed difference in the 
timing of the superinfections may have influenced the observed genetic diversity. Both CAP256 
and CAP237 were superinfected closer to the time of enrolment allowing greater time for 
recombination to occur which would reduce the distance between strains.  CAP281 on the other 
hand was superinfected just prior to one year post infection, with limited time for 
recombination and this distance likely reflected by the distinct viral populations which co-exist 
at 12 months infection. From the C2-C3 region alone it is difficult to confidently distinguish 
whether recombination had occurred in both CAP256 and CAP237. However previous work by 
F. Treunicht (University of Cape Town) had determined the virus present at six months post 
infection in CAP256 to be a recombinant. As yet no further analysis has been carried out on 
CAP237.   
However individuals CAP30 and CAP177 also exhibited higher DNA distances than the other 
individuals screened with distances above the 75 percentile. CAP177 is a potential dual 
infection as a different variant has been detected in the cervicovaginal cavity at enrolment (P. 
Moore. Pers. Comm). This may account for the higher DNA distance observed in this individual, 
however as dual infection has not been confirmed in this individual they are characterized here 
















homogenous viral population which diversified over the first year of infection; the 
diversification over the first year of infection may have resulted in a higher DNA distance due to 


















































Figure 2.6 Pairwise DNA distance of each CAPRISA individual over the first year of infection. The bars with the small 
checkered pattern indicate those individuals identified as superinfected, the larger checkered bars indicate those 
individuals proposed to have heterogeneous primary infections and the striped bars indicate those individuals with 
homogenous primary infections. The red lines indicate the inter-quartile range and the median pairwise DNA 
















When the individuals were grouped according to their heteroduplex mobility assay results: 
homogenous, heterogeneous or superinfected, the median DNA distance of each group (0.5%, 
2% and 11.2%, respectively) indicated that the superinfected individuals had significantly 
higher pairwise DNA distance than those infected with homogenous and heterogeneous viral 
populations (p= 0.005) (Figure 2.7A).  
It would be expected that the genetic distance in a dual infected individual would be greater 
than or equivalent to the genetic distance between two epidemiologically unlinked viruses in 
the same cohort. Therefore the median pairwise intra-participant DNA distance was determined 
at twelve months post infection for all the individuals (n=20) screened in this study and was 
found to be 5.7%. All of the superinfected individuals had a DNA distance greater than the 
median intra-participant DNA distance, providing further evidence that these individuals were 






































Figure 2.7 Comparison of the observed pairwise DNA distance over the first 12 months of infection in individuals 



















2.3.4 Effect of superinfection on disease progression  
 
Several studies have shown faster disease progression to be associated with superinfection; 
therefore we wanted to determine if any of the superinfected individuals in this study exhibited 
an accelerated disease progression.  
CAPRISA individual CAP237 (Figure 2.8) was superinfected sometime after enrolment and prior 
to three months post infection. There was a substantial change in viral load at the time of 
superinfection (>1 log) as well as a decline in CD4+ T-cell numbers from 620 cells/ul to 434 
cells/ul. Some control of viremia was regained subsequent to superinfection however this 
control was interspersed with arbitrary spikes in viral load for the remainder of follow up. 
However, these spikes in viral load never exceeded 40 000 copies suggesting some degree of 
control over both viruses.  Her CD4 cell counts fluctuated throughout the four years of follow up 
however her cell numbers never declined below 200 cells/ ul for longer than one sampling 
point. Thus for this individual although their control was not consistent their disease 


















Figure 2.8 The viral load profile of CAPRISA Individual CAP237 over the first 50 months of infection, showing their 
HIV-1 plasma viral load and CD4+ T cell count. The viral load is indicated by the solid blue line and the CD4 cell count 
by the solid red line. The window period during which superinfection occurred is indicated on the figure by the 
dotted red lines. 
For CAPRISA individual CAP256 (Figure 2.9), the superinfection occurred between three and 
four months post infection. Superinfection was associated with a greater than 1 log change in 
viral load, which was accompanied by a sharp decline in CD4+ T-cell numbers. Viral replication 
was reduced temporarily following superinfection suggesting some control of the 
superinfecting virus however this was not sustainable and this individual maintained high viral 
loads for duration of follow-up (6 years) (> 100 000 copies per ml). The CD4+ T cell numbers 
were above 500 cells/ul prior to superinfection and after superinfection continued to decline 
over the next twenty months to a low of 246 cells/ul.  This individual had high viral loads and 
low CD4 counts, and initiated therapy after 4.5 years when she met the South African criteria 

















Figure 2.9 The viral load profile of CAPRISA Individual CAP256 over the first 70 months of infection, showing their 
HIV-1 plasma viral load and CD4+ T cell count. The viral load is indicated by the solid blue line and the CD4 cell count 
by the solid red line. The window period during which superinfection occurred is indicated on the figure by the 
dotted red lines and the initiation of antiretroviral therapy is indicated by the dotted green line. 
The disease profile observed for CAPRISA individual CAP281 differed from CAP256 as prior to 
superinfection this individual had viral loads below the level of detection (<400 copies/ ml) 
(Figure 2.10). Superinfection occurred at around 11 months and was associated with an 
increase in viral load to levels similar to the initial infection (~6000 copies /ml).  This individual 
regained control of her viral load after superinfection and maintained high CD4 counts of ~1000 
cells/ul. These results suggest that this individual was better able to control the second virus 
than individual CAP256 and there was no evident acceleration of the disease as a result of the 
superinfection.  The time to a CD4 count of 350 cells per ul was three years for CAP281 
compared to two years for CAPRISA 256. Considering the control that this individual had shown 
previously it is interesting that after three years this individual started to lose control of their 
viremia. Further examination of sequences from later time points may provide some insight as 

















Figure 2.10 The viral load profile of CAPRISA Individual CAP281 over the first 27 months of infection, showing their 
HIV-1 plasma viral load and CD4+ T cell counts. The viral load is indicated by the solid blue line and the CD4 cell 
count by the solid red line. The window period during which superinfection occurred is indicated on the figure by the 
dotted red lines. 
2.4 Discussion 
 
Several studies have determined the frequency of HIV-1 superinfection. Most studies were 
carried out in regions where multiple subtypes circulate and have reported incidences of 
superinfection of 4% per year compared to an 8% per year incidence of primary infection (28). 
There are few studies in regions dominated by a single circulating subtype although one study 
found a 2.8% per person year incidence of superinfection in a subtype B infected cohort which 
was screened longitudinally for six years (108). Thus far there have been no incidence studies of 
HIV-1 superinfection in individuals infected with HIV-1 subtype C. In this study we found 10.5% 
of individuals superinfected (2/19), which is similar to the original incidence of infection of 
7.2% (117). We found superinfection was not always associated with rapid disease progression 
with two of the superinfected individuals effectively controlling their viruses and only one 
















Cases of superinfection have often been identified as a result of a sudden unexpected increase in 
viral load (56, 79, 124). In this study all three superinfected individuals exhibited an increase in 
viral load which coincided with the estimated timing of HIV-1 superinfection. This spike in viral 
load was presumably as a result of the increased viral burden resulting from the presence of a 
second virus.  
With respect to timing two individuals were re-infected within four months of initial infection 
(CAP237 and CAP256) whereas the other was re-infected at closer to one year post infection 
(CAP281). For individual CAP281 the superinfection occurs much later at closer to one year 
after the initial infection (Figure 2.10). These results suggest susceptibility to superinfection is 
not restricted to the early stage of infection where CTL immune responses are generally more 
focused and there is low or no autologous neutralizing antibody responses as superinfection of 
CAP281 occurred when both arms of the adaptive immune responses would have been mature.   
There have been several reports of individuals presenting protective HLAs who following 
superinfection, progressed to AIDS (16, 102).  In the first study the individual presented the 
B*27 protective HLA and was controlling their initial infection, after superinfection the 
individual lost control of their viral population through the development of an escape mutation 
in the KK10 epitope (102). In another study the B*57+ long-term non-progressor was proposed 
to have been initially infected with a weaker virus, this first virus was found to be nef-defective. 
After ten years of viral control this individual was superinfected with a fully competent virus 
and resulted in outgrowth of a recombinant virus which resulted in disease progression. In this 
individual, the neutralizing antibodies were unable to neutralize the second virus and only a 
very weak gag-specific CTL response had developed prior to superinfection (16). Therefore the 
presence of a protective HLA does not necessarily indicate that the individual will not progress 
to disease but rather the nature of the infecting virus, together with quantity and quality of the 
immune responses, is also important. CAP256 was B*5802 positive, an allele which has been 
















effectively control the primary infecting virus, not the viruses after superinfection. This 
individual progressed to AIDS within 56 months of infection when her CD4+ counts reached 200 
cells/ul and she initiated therapy.  CAPRISA individual CAP281 on the other hand was B*4201 
and B*4403 positive, both HLAs which have been associated with lower viral loads, higher CD4 
cell numbers and slower disease progression (59, 65). She maintained a relatively low viral load 
up until the time of the superinfection, and after spike in viral load associated with 
superinfection regained control of the viruses reducing viral loads to the levels observed prior 
to superinfection (<400 copies/ml). These results suggest that HLA plays a dominant role in 
defining disease progression, even after superinfection.  However at the time of this study, by 40 
months post infection the viral load in CAP281 was increasing with a concomitant reduction in 
CD4 counts suggesting that this control may not be durable.    
One of the consequences of HIV-1 superinfection is the explosion of diversity that results from 
two strains infecting a single individual. The typical intra-subtype distance among 
epidemiologically unrelated sequences is approximately 11%, while that expected of viruses 
from different subtypes or the inter-subtype distance is between 21 and 30% (73). 
Superinfected individuals had a median pairwise DNA distance of 11.2% when comparing 
viruses from enrolment and 12 months infection.  The DNA distances observed over the first 
year of infection in superinfected individuals was substantially higher than individuals infected 
with homogenous or heterogeneous quasispecies. This indicates a much greater diversity 
within these individuals. Diversity is a crucial aspect of the virus’s pathogenic ability as it 
enables evasion from immune recognition through mutagenesis and recombination (27).  
HIV-1 evolves to adapt to the host environment, escape immune responses and resist 
antiretroviral therapy (106). A study by Shankarappa et al. (1999) showed that evolution within 
the envelope gene increases over the course of infection and peaks at the onset of AIDS (95) 
suggesting that it may play some role in disease progression. Viral diversity has been previously 
















observed higher viral diversity seen in the superinfected individuals should provide their 
quasispecies with a substantial advantage by increasing the probability of variants with 
enhanced fitness.  
The incidence of HIV-1 superinfection (10%) over the first year of infection suggests that it is 
occurring frequently in the CAPRISA 002 cohort. However it may not have pathogenic 
implications as seen in the case of CAP81 who is a slow progressor.  However, superinfection 
does provide increased sequence diversity which can potentially facilitate escape.  This will be 

















Chapter 3: Genetic characterization of superinfecting viruses  
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HIV vaccine design is complicated by the genetic variability of the virus which results in genetic 
mismatch between the vaccine and the challenge virus. This mismatch may make the immune 
responses generated by the vaccine ineffective and it is proposed that this was a contributing 
factor to the failure of the Merck Ad5 vaccine trial (19). It is not yet understood what immune 
protection is required to protect against infection or re-infection with HIV however studying 
HIV superinfection and its correlates of protection may provide some insight. Understanding the 
selective forces which are acting on viral populations and the constraints on immune escape is 
central to developing an HIV-1 vaccine. Therefore examining the genetic evolution of two 
different viruses in the same individual, the role of recombination in driving HIV diversity,  as 
well as the effect that host selective pressures have on these viruses will be important for the 
development of a vaccine which will elicit responses of considerable breadth. 
Viruses within individuals with dual infection evolve both through HIV recombination between 
different virus strains, as well as through accumulation of point mutations.  The accumulation of 
point mutations is a slower evolutionary route compared to recombination as an average only 
one substitution occurs per viral genome per generation (82), whereas a combination of 
multiple substitutions are exchanged through recombination in a single cycle of replication. The 
rate of recombination is estimated to be 2.8 times per genome per replication cycle (129) 
compared to point mutations which have a rate of one nucleotide substitution per genome per 
replication cycle (82). Recombination has the additional advantage in that polymorphisms 
which are gained during recombination have already proven to be viable in the parent virus 
therefore it is less likely for recombination to result in a deleterious mutation than it is during 
the accumulation of point mutations (85). In the scenario of superinfection, recombination 
between the initial and superinfecting viruses could lead to the generation of beneficial 
combinations of mutations, as well as the loss of potentially deleterious mutations. The 
















way, recombination can accelerate disease progression directly by increasing the replicative 
fitness of the virus, or indirectly as it allows for faster escape from host immune pressures (90).   
Examining full-length HIV-1 genomes provides information with more scientific power to 
characterise viral evolution, immune escape, patterns of recombination and viral pathogenesis.  
To date, only two superinfection studies have been published that have examined the full HIV-1 
genome, both of which characterised viruses in a single individual (5, 102). Streeck et al., found 
that established and effective CTL responses to the initial infection were lost as a result of 
superinfection, large due to recombination between the two viruses. The superinfecting virus 
was carrying amino acid changes in epitopes which were associated with escape and following 
infection, the pattern of recombination that occurred between the two viruses appeared to be 
driven by selection for the amino acid residues associated with escape. This loss of CTL 
recognition subsequently resulted in loss of immune control in this individual and thus faster 
disease progression (102). Similarly, Altfeld et al., found that superinfected individuals who had 
substantial CTL responses to their initial infection were unable to protect against re-infection 
due to CTL escape mutations in the superinfecting virus (4).  
This study examined the evolution of the full-length HIV-1 genome over time in two individuals, 
CAP256 and CAP 281, who had been superinfected at around 3 and 11 months post infection 
respectively.  We aimed to determine if HLA class I restricted epitopes potentially recognised by 
cytotoxic T lymphocyte responses to the initial virus, were found in the superinfecting viruses. 
In addition, we aimed to determine if the superinfecting virus had a greater genetic distance 





















Two individuals from the CAPRISA002 Acute Infection cohort, who had been identified as 
superinfected, CAP256 and CAP281, (Chapter 2) were selected for characterisation of their 
evolving viral populations.   
3.2.2 RNA Extraction  
 
Plasma samples were obtained from before, after and at the estimated time of the 
superinfection.  RNA was extracted the Qiagen Viral RNA Extraction Kit as per manufacturers’ 
instructions (Qiagen, Valencia USA). The kit yielded 50ul of extracted RNA from a 200ul plasma 
sample, however for low viral loads  a double extraction was performed where 400ul of plasma 
is used to generate 50ul of RNA. The RNA was then stored at -80°C until it was required. 
3.2.3 Reverse Transcription 
 
OligodT was used to generate HIV-1 full genome cDNA using the Superscript III reverse 
transcription kit (Roche, Basel Switzerland). This primer consists of a string of 20 
deoxythymidylic acid residues and hybridizes to the poly (A) tail of mRNA thus initiating 
synthesis of a complementary strand. A mixture of 25ul of the extracted RNA, the primer 
OligoDT (1mM)(Integrated DNA Technologies, Coralville USA) and dNTPs (0.4uM) was made 
up. Following incubation at 65°C for 5 minutes, the solution was cooled to 4°C until 25ul of the 
mastermix was added to it. The mastermix was composed of the 5X First Strand Buffer, 2.5ul of 
DTT (40mM), 7.5 ul of DEPC treated water, 1 unit of RNase Inhibitor and 2ul of the enzyme 
Superscript III. All reagents excepting the primer, the dNTPs and the water were included in the 
reverse transcription kit. This tube was then heated at 45°C for 2 hours followed by denaturing 
of the enzyme at 70°C for 15 minutes, finally 1ul of RNase H (Invitrogen, Carlsbad USA) was 
















out using the Applied Biosystems 2720 Thermal Cycler (Applied Biosystems, Carlsbad, CA USA) 
and the cDNA was stored at -20°C until it was required. 
3.2.4 Amplification of the HIV-1 Genome 
 
Nested amplification was carried out which generated an approximately 9kb fragment covering 
the genome from the beginning of gag to the end of nef using  the Expand Long Template PCR 
Amplification Kit (Roche, Basel Switzerland).  Although the conditions of this reaction had been 
optimised previously in some cases the amount of cDNA added needed to be adjusted to get 
amplification.  
The first round reaction typically consisted of 18.2ul of distilled water, dNTPs (0.4mM), 0.3ul of 
each primer (50pM/ul), 23.25ul of distilled water, 10X Buffer 1, 0.75ul of Expand enzyme and 
1ul of cDNA. The primers used in the first reaction were 1.U5C, 1.U5Cb and 1.3.3pIC (Table 
3.1)(Integrated DNA Technologies, Coralville USA). The cycling conditions consisted of an initial 
denaturation step at 94°C for 2 minutes, followed by 10 cycles of denaturation at 94°C for 10 
seconds, annealing at 60°C for 30 seconds and elongation at 68°C for 8 minutes. A further 20 
cycles of amplification were then carried out which consisted of denaturation at 94°C for 10 
seconds, annealing at 68°C for 30 seconds and elongation at 68°C for 8 minutes with an 
additional 15 seconds every cycle. The amplification concluded with a final elongation step at 
68°C for 10 minutes and finally cooling to 4°C. A negative control was run with each set of 
reactions, where the negative control had distilled water added instead of cDNA, to ensure no 
contaminants were present. All amplifications were carried out on either the Applied 
Biosystems 2720 Thermal Cycler (Applied Biosystems, Carlsbad, CA USA) or the Applied 

















Table 3.1 PCR Primers used for the Amplification of HIV-1 Genome 




1.U5C 5’-GGGTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT 538–571 Forward 
1.U5Cb 5’-GGGTGAGTGCTCTAAGTAGTGTGTGCCCATCTGT 538–571 Forward 
1.3.3pIC 5’-GGGACTTAGAGCACTCAAGGCAAGCTTTATTG 526–557 Reverse 
2.U5C 5’-GGCCGCGGATCCAGTAGTGTGTGCCCGTCTGTTGTGTGACT 540-580 Forward 
2.3.3pIC 5’-GGCCGCGCGGCCGCTAGAGCACTCAAGGCAAGCTTTATTGAGGCTTA 519–565 Reverse 
 
The second round reaction or the inner reaction had 18.5ul of distilled water, 0.3ul of each 
primer (50pM/ul), 0.9ul of dNTPS (0.4mM), 23.25ul of distilled water, 10X Buffer 1, 0.75ul of 
the Expand enzyme and 1ul of the PCR product from the first round reaction. The primers used 
in the second round reaction were 2.U5C and 2.3.3pIC (Table 3.1)(Integrated DNA Technologies, 
Coralville USA). The cycling profile used was the same as that used for the first reaction. Once 
again a negative control was included to ensure there was no contamination and amplification 
was carried out on the Applied Biosystems 2720 Thermal Cycler or the Applied Biosystems 
GeneAmp PCR System 9700 (Applied Biosystems, Carlsbad, CA USA).  
3.2.5 Visualization of DNA Product by Agarose Gel Electrophoresis 
 
Following the second nested amplification, the PCR products were visualized on a 1% TAE 
agarose gel (Appendix C). The loading dye contained Gel Red (Biotum, Hayward CA USA) and 
was added to each sample as well as the molecular weight marker. Gels were viewed under UV 
light using the UVIpro Silver UV box (UVItec, Cambridge United Kingdom).  
3.2.6 Purification and Sequencing of PCR Product 
 
For the products which were successfully amplified, re-amplification of the first round product 
was carried out to generate sufficient DNA for sequencing.  PCR products were purified using 
the Zymo DNA Clean and Concentrator 5 Kit (Zymo Research Corporation, Orange USA) 
generating about 60ul of DNA product with a concentration of between 100 and 300ng/ul. 
















terminator cycle-sequencing kit (Applied Biosystems, Carlsbad, CA USA) and then run on a 
genetic analyzer. A table of the primers used are included in the appendix (F1). 
3.2.7 Sequence Assembly and Phylogenetic Analysis 
 
The chromatograms were then assembled using Sequencher (Gene Codes Corporation, Ann 
Arbor USA). Assembled sequences were aligned with other HIV-1 whole genome sequences 
from other CAPRISA individuals as well as a group of subtype C sequences obtained from the 
Los Alamos HIV Sequence Database (www.hiv.lanl.gov) using Bioedit Sequence Alignment 
Editor Version 7.0.9.0 (51) and these alignment files were then imported into Mega Version 4.0 
(104) to generate a phylogenetic tree using the neighbour joining method.  
Sequence alignment files for each individual, containing the sequences for each of the time 
points amplified, were uploaded into the Highlighter tool on the Los Alamos HIV Sequence 
Database (www.hiv.lanl.gov). 
3.2.8 Recombination Analysis 
 
Recombination Identification Programme (RIP) was used to identify recombination breakpoints 
(www.hiv.lanl.gov ). To illustrate the regions of recombination from the perspective of the genes 
within the genome the results of the RIP scan were then used to draw the recombinant virus. 
This was done using the Recombinant Drawing Tool on the Los Alamos HIV Sequence Database 
(www.hiv.lanl.gov ) which uses the recombination breakpoints from the RIP results and maps 

















3.2.9 Epitope Coverage of Superinfecting Virus by Initial Virus 
 
The Epicover tool from the Los Alamos HIV Immunology Database (www.hiv.lanl.gov ) was used 
to determine the extent of coverage of all 9-mers in the whole genome sequence of primary 
virus infection compared to the superinfecting virus.   
3.2.10 HLA Typing 
 
The four digit high-resolution HLA typing was performed at the National Institute of 
Communicable Diseases; Johannesburg, South Africa by C. Grays’ laboratory. The Pel-Freez DNA 
Isolation Kit (Pel-Freez, Arkansas USA) was used to extract DNA from either granulocytes or 
PBMCs. Exons 2, 3 and 4 were sequenced using the Atria AlleleSeqr kits (Abbott) and Assign-
SBT 3.5 (Conexio Genomics, Applecross Western Australia) to type alleles A, B and C 
respectively. Sequence specific primers were used to resolve any ambiguities as a result of 
either identical heterozygote combinations or polymorphisms outside the sequenced exons.  
3.2.11 Identification of CTL Escape Mutations   
 
To determine where CTL escape mutat ons were present in epitopes of the superinfecting virus 
the sequences were studied for amino acid changes in either the putative HLA restricted epitope 
or in the flanking regions. Putative epitopes were identified using the HLA data for each 
individual as well as the list of published epitopes on the Los Alamos Immunology Database 
(www.hiv.lanl.gov). HLA-associated polymorphisms associated with subtype C chronic infection 
were also taken into consideration (69, 89). Substitutions within an epitope that resulted in 
change from a high frequency residue with a low frequency residue were classified as escape. 
These amino acid frequencies were determined using an alignment of 100 sequences from 
South African subtype C infected individuals obtained from the Los Alamos Sequence Database 
















and where amino acid changed to consensus from low to high frequency amino acid were 
classified as reversions. 
3.2.12 Statistical Analysis     
Most of the figures in this chapter were generated using GraphPad Prism 4.0 (GraphPad 
Software Incorporated, USA). Both the Kruskal-Wallis and the Mann Whitney tests were used to 
determine whether the epitope coverage of the superinfecting virus by the initial virus was 
significantly better or worse than other CAPRISA sequences.  
3.3 Results 
 
To examine the genetic differences between the initial and superinfecting strain the full length 
genome of the viruses in superinfected individuals CAP256 and CAP281 were amplified. For 
CAP256 four sequences were generated from four different time points (Table 3.2). There were 
eight sequences generated from six different time points (Table 3.2) for CAP281. For both 
individuals both the initial and superinfecting viruses were amplified. 
Table 3.2 Participant Data 
Participant ID Presenting HLA Time Point Viral Load (copies/ml) Sequence Source 
CAP256 
A*2902; A*6601;  
B*1503;B*5802; 
Cw*0401;Cw*0602 
Enrolment 56500 H. Harvey 
3 MPI 51600 F. Treunicht 
4 MPI 2390000 H. Harvey 
6 MPI 626000 F. Treunicht 
CAP281 
A*0214; A*3001;  
B*4201;B*4403; 
Cw*0401;Cw*1701 
Enrolment 4060 H. Harvey 
3 MPI 2770 H. Harvey 
6 MPI 657 H. Harvey 
7 MPI 1230 H. Harvey 
10 MPI 5020 H. Harvey 
11 MPI 5220 H. Harvey 
HLA*B*5802 is associated with rapid progression, HLA B*4201 is associated with lower viral loads and slower disease progression; 

















3.3.1 Characterisation of full-length genome sequences over time 
 
The full-length HIV-1 genome was amplified and sequenced at different intervals over time for 
individuals CAP256 and CAP281 (Table 2.2). Similar to the C2-C3 phylogenetic clustering 
(Figure 2.7), the FLG sequences from CAP256 separated out between three and four months 
post infection, while sequences from CAP281 separated out between ten and eleven months 
post infection (Figure 3.1). In CAP256 the four months post infection sequences, and the 
CAP281 eleven month post infection sequences, showed no evidence of recombination in any of 


















Figure 3.1 Neighbour joining phylogenetic tree of HIV-1 full length genome sequences (9000bp) from the CAPRISA 
cohort and reference sequences obtained from the Los Alamos HIV database (www.hiv.lanl.gov). The black diamonds 
indicate sequences generated from individuals in the CAPRISA cohort and the superinfected individuals CAP256 and 
CAP281 are indicated as the pink and turquoise circles respectively. Bootstrap values greater than 70% are indicated 
and the scale bar represents a DNA distance of 0.01%. 
3.3.2 Recombination in CAPRISA Individual CAP256    
 
The shift in viral populations can be visualised using highlighter plots which illustrate the 
number of nucleotide mismatches to the initial infecting virus (Figure 3.2A). At six months post 
infection, there is evidence of recombination between the primary infecting virus and the 
superinfecting virus, with the virus at this time point retaining a substantial portion of the 


















































































































(Figure 3.2B), evolution of the initial infecting strain can be visualised with the seven months 
post infection virus containing a substantial deletion at the start of envelope which may be an 
artefact of the PCR amplification.  
                                                                                 
Figure 3.2 Highlighter plot of HIV-1 whole genome sequences at selected time points from A) CAPRISA individual 
CAP256 and B) CAPRISA individual CAP281 with a and b indicating different amplicons from the same time point. 
Each coloured line indicates a nucleotide mismatch with the primary infecting sequence. The colors in the highlighter 
plot represent changes to: A = Green, T = Red, G = Orange, C = Light Blue, IUPAC = Dark Blue and Gaps = Grey.  The 
scale at the bottom refers to the number of base pairs. 
The recombination patterns of viral populations in CAP256 over the three months following 
superinfection is more clearly illustrated  using a recombination highlighter plot which 
distinguishes regions of the genome that originate from each parent (primary and 
superinfecting virus)(Fig 3.3). At 6 months post infection the recombinant is composed 
predominantly of the sequence from the superinfecting virus however there are four main 
regions where the sequence from the primary infecting virus was incorporated including 
regions of p17, a portion of reverse transcriptase, the majority of integrase, and V1/V2 envelope 
loops (Figure 3.3).    































Figure 3.3 Recombination highlighter plot illustrating recombination in the 6 months post infection virus from 
CAPRISA individual CAP256. The plot highlights matches between the recombinant virus and its parent viruses. 
Therefore where the recombinant was most similar to either the primary infecting virus (blue) or the superinfecting 
virus (red) it is highlighted in the same colour as that parent. Regions where recombination occurred are indicated by 
the green squares.  
To confirm the results of the recombination highlighter plot, the RIP recombination programme 
was used to query the six months post infection sequence (www.hiv.lanl.gov ). The results of the 
similarity plot (Figure 3.4) reflects those seen in the highlighter plot, with the majority of the 
virus at six months post infection comprised of the superinfecting virus and four regions where 
the sequence originates from the primary infecting virus. These four regions in the RIP plots are 
in positions which are similar to the four regions indicated by the highlighter plot. 
  




















Figure 3.4 Illustration of the recombinant virus present at 6 MPI indicating regions of recombination between the 
primary infecting and superinfecting viruses. To determine the breakpoints of the recombinant virus a similarity plot 
was generated using a sliding window of 200 and a confidence interval of 99% and shows the similarity between the 
6 MPI sequence and each of its parents, the primary infecting and superinfecting viruses. At the top of the plot the 
colour of the bottom line indicates the best match to the 6 MPI sequence with red indicating the primary infecting 
sequence and green the 4 MPI sequence. The presence of the top line indicates whether that match is significantly 
better than the other parent.    
As we do not have sequences generated after eleven months post infection for CAP281, it was 
not possible to track evolving recombinant viruses in this individual. 
3.3.3 Genetic Distance between the Initial and Superinfecting Viruses 
 
To determine if the superinfecting virus was more different from the initial virus compared to 
viruses infecting other CAPRISA participants, a similarity plot was drawn. The overall similarity 
between the initial infecting virus in CAP256 and the superinfecting strain was relatively high 
(>72% across the genome) with the least similarity seen in vpu (82%) and envelope (88%), and 
the highest similarity seen in gag (92.5%) and pol (95%)(Figure 3.5).  In the same way CAP281 
had the least similarity between the initial and superinfecting viruses was observed in vpu 
(85%) followed by envelope (86.8%)(Figure 3.6). Once again gag (93%) and pol (95.5%) were 

















Figure 3.5 Similarity plot for CAP256 primary infecting sequence. This plot shows the percentage nucleotide 
similarity of the primary infecting sequence of CAP256 to the 4 MPI sequence (purple), to sequences from other 
CAPRISA participants (pink) and to the consensus C sequence from South Africa (turquoise). A sliding window of 600 
nucleotides was used. 
In CAP256 the consensus, generated from sequences acquired from CAPRISA002 women in 
acute infection, was closest to the primary infecting virus, as expected.  The consensus C 
sequence was generated by aligning several whole genome sequences generated from 
participants in the CAPRISA 002 Acute Infection Study. A consensus was then generated from 
this alignment using the Consensus Maker tool on the Los Alamos HIV Sequencing Database 
(www.hiv.lanl.gov ).The superinfecting virus appeared to have greater DNA distance in gag and 
pol compared to other CAPRISA sequences.  These results suggest that, at least with gag and pol, 
greater genetic distance may be one factor enabling superinfection.  This is similar to previous 
studies which have suggested that the genetic distance between the initial and superinfecting 
virus may be a factor in the occurrence of superinfection, where more distantly related viruses 
















A different trend is observed in CAP281 where the superinfecting virus lies in the middle of the 
other CAPRISA sequences when compared to the primary infecting virus. The similarity 
between the initial and superinfecting viruses is greatest in gag and pol with the superinfecting 
virus being considerably different in envelope, however these differences are no greater than 
those of other CAPRISA viruses. These results suggest that CAP281 is as different from the 
primary infecting virus as other circulating CAPRISA sequences and that for this individual the 
genetic distance may not have played a role in allowing superinfection to occur. 
 
 
Figure 3.6 Similarity plot for CAP281 primary infecting sequence. This plot shows the percentage similarity of the 
primary infecting sequence of CAP281 to the 11 MPI sequence (purple), to sequences from other CAPRISA 
participants (pink) and to the consensus C sequence from South Africa (turquoise).  A sliding window of 600 
nucleotides was used. 
3.3.4 Epitope Coverage of Superinfecting Virus by Initial Virus 
 
To determine the effect of epitope diversity on superinfection, we estimated the epitope 
















CAP281.  We compared the primary infecting virus to the superinfecting virus and then 
calculated the percentage of peptides of epitope-length in the superinfecting virus that match it. 
The primary infecting virus was also measured against sequences from other CAPRISA 
individuals to determine whether the coverage of the superinfecting virus by the primary 
infecting virus was any better than with any other viruses circulating in this region.  
 
The results from CAPRISA individual CAP256 (Figure 3.7) suggest that there was less epitope 
coverage in the gag, vpu and rev proteins by the primary infecting virus. In the other proteins 
epitope coverage by the primary infecting virus was either similar, or in fact better, than other 
CAPRISA sequences. When we analyzed epitope coverage by the primary virus across the 
proteome, the difference in coverage across the genome was found to be highly significant (p= 
<0.0001)(Kruskal-Wallis Test). Further analysis of individual proteins showed that Gag from 
the superinfecting virus had significantly lower coverage by the primary virus compared to 
CAPRISA sequences (Mann-Whitney, p= 0.0353) as did Vpu (0.0156). For CAP256 the coverage 
of the CAPRISA viruses by the CAP256 primary infecting virus ranged from 18.2% to 58.5% 
with a mean of 22.6%. The coverage of the superinfecting virus ranged from 9.2% to 58.6% with 
a mean of 29.1%, suggesting that although the mean coverage was higher there were gene 
regions where the coverage was substantially lower. The lack of coverage in these regions may 












































































































































































Figure 3.7 The epitope coverage by the CAP256 primary infecting sequence of the superinfecting virus and CAPRISA 
sequences (n=20) in each gene. For the analysis an epitope length of 9 amino acids was used and the coverage 
denotes the proportion of these 9-mers that were present in the primary infecting sequence averaged over all of the 
sequences analysed.   
For CAPRISA individual CAP281 the trend was different to CAP256 as there were no regions of 
the genome in which the epitope coverage was lower than that observed in the other CAPRISA 
individuals (Figure 3.8) however the coverage of the superinfecting virus by the primary was 
found to be significantly different to that of the CAPRISA sequences (p= <0.0001). Interestingly 
in CAP281, the epitope coverage by the primary virus was significantly higher in Gag (p= 
0.0071), Vpr (p= 0.0319) and Vpu (p= 0.0156) of the superinfecting virus than the other 
CAPRISA sequences. For the CAPRISA viruses the coverage by the CAP281 primary infecting 
virus ranged from 20.2% to 58.3% with a mean of 32.6%. This was only slightly lower than that 
of the superinfecting virus whose coverage of the primary infecting virus ranged from 20.2% to 




















However, this coverage never extends above 60% suggesting that the overall coverage by the 
primary infecting virus was relatively poor and that the CTL responses generated by the first 
infection may not be substantial enough to protect against re-infection. Together these results 
show that in CAP281, the superinfecting viruses were not more different from the primary 
infecting virus than the CAPRISA sequences; however differences were detected in epitope 
coverage in some CAP256 proteins from the superinfection strain. This suggests that for 
CAP281 the recognition of the second virus would have been the same as if they had been 
exposed to any of the other CAPRISA sequences, however for CAP256 the primary infecting 
virus appeared to differ from the CAPRISA sequences to a greater extent than the CAP281 virus 































































































































































































Figure 3.8 The epitope coverage by the CAP281 primary infecting sequence of the superinfecting virus and CAPRISA 
sequences (n=20) in each gene. For the analysis an epitope length of 9 amino acids was used and the coverage 
denotes the proportion of these 9-mers that were present in the primary infecting sequence averaged over all of the 
sequences analysed. 
3.3.5 Mapping of HLA Restricted Epitopes in Primary and Superinfecting viruses 
 
The epitope coverage tool does not take HLA into consideration.  To further refine this analysis 
we identified putative epitopes associated with the HLA alleles of CAPRISA individuals CAP256 
and CAP281, in both the primary infecting and superinfecting virus. We aimed to determine if 
CTL escape mutations in the superinfecting virus was the result of lack of immune recognition 
of the second infecting virus.  We defined epitopes in two ways:  (i) optimal epitopes, as defined 
by Frahm et al.(35), which have been experimentally shown to be restricted by the HLA in 
question; (ii) predicted epitopes are those which have been mapped to a peptide but where the 
optimal epitope has not yet been defined. The HLA alleles of CAP256 and CAP281 are described 




















(Table 3.3 and Table 3.4). Any changes in epitopes proven in the literature to be associated with 
loss of recognition were classified as escape mutations, whereas putative escape were changes 
in amino acid residues within epitopes predicted to result in loss of HLA restriction using tools 
such as NetMHCpan and MotifScan.  As escape has been associated with a change from high 
frequency to low frequency amino acids, we also took the amino acid frequency into 
consideration. A detailed summary of the change in sequence over time for each epitope is 
provided in the appendix for both the optimal and predicted epitopes. 
Table 3.3 Summary of HLA associated Optimal and Predicted Epitopes across the HIV-1 Genome of CAPRISA 
individual CAP256 showing their location, their restricting HLA and their classification 
 
Epitopes were identified using the list of published epitopes on the Los Alamos Database (www.hiv.lanl.gov).  
*Epitope sequence with respect to consensus subtype C 
Bold residues indicate the residues at which amino acid changes were observed 
 
For CAPRISA individual CAP256, eleven optimal epitopes were identified of which six were 
identified with differences in sequences between the primary infecting and superinfecting virus 
(Table 3.3). Of the six epitopes, four contained potential escape mutations in the superinfecting 
















identified with differences in amino acid residues between the primary infecting and 
superinfecting virus (Table 3.3). Three of these epitopes contained potential escape mutations 
in the superinfecting virus. The presence of escape mutations in these epitopes suggests that 
CTL recognition of these seven epitopes would have been diminished in the superinfecting 
virus.  
For CAP281, of the six optimal epitopes identified in this individual there were five identified 
with differences in sequence between the primary infecting and superinfecting virus (Table 
3.4). Of these five epitopes there were two which had amino acid residues associated with 
escape. Of the 21 predicted epitopes identified, ten contained differences in sequence between 
the primary infecting and superinfecting viruses (Table 3.4). Of these ten epitopes there were 

















Table 3.4 Summary of HLA associated Optimal and Predicted Epitopes across the HIV-1 Genome of CAPRISA 
individual CAP281 showing their location, their restricting HLA and their classification 
 
Epitopes were identified using the list of published epitopes on the Los Alamos Database (www.hiv.lanl.gov ) 
*Epitope sequence with respect to consensus subtype C 
Bold residues indicate the residues at which amino acid changes were observed 
 
A summary of the total number of epitopes with putative escape, reversion and that were 
conserved between the initial and superinfecting viruses in CAP256 is presented in Figure 3.9 
and for CAP281 in Figure 3.10. 
For CAPRISA individual CAP256, of their optimal HLA associated epitopes, most were conserved 
between the initial and superinfecting strains (Figure 3.9A). A similar trend was observed with 
the predicted epitopes where most were conserved between the initial and superinfecting 
viruses (Figure 3.0B).Of the optimal epitopes of CAPRISA individual CAP281 there were equal 
















predicted epitopes contained a much larger number that were conserved between the initial 
and superinfecting viruses. 
These results for both CAP256 and CAP281 suggest that even with more than half of the 
epitopes conserved between the two viruses this was not sufficient to protect against re-
infection. 
 
Figure 3.9 Frequencies of Escape, Reversion and Conservation of HLA associated epitopes within CAPRISA individual 




































































Figure 3.10 Frequencies of Escape, Reversion and Conservation of HLA associated epitopes within CAPRISA 




















































































3.3.6 Distribution of Escape Epitopes across the HIV-1 Recombinant Genome of CAP256 
 
To determine whether selective pressure from the host immune response was driving the 
pattern of recombination we mapped the escape mutations in both the primary virus and the SI 
onto the HIV-1 genome (Figure 3.13 and Figure 3.14). The recombinant virus at 6 months 
predominantly contained regions from the superinfecting strain and thus the optimal and 
putative escape mutations in originating from the superinfecting strain were preserved.  
Interestingly, all of the regions of the primary infecting virus that were incorporated were those 
which carried escape mutations suggesting that for this individual recombination of the initial 
and superinfecting virus may have occurred so as to generate a virus with an advantage.  This 
included the V1V2 regions which have been shown in a separated study to be associated with 
escape from neutralizing antibodies (P. Moore, NICD, Pers. Communication). These results 
indicate that superinfection may drive more rapid CTL escape through recombination between 










Figure 3.13 Distribution of HLA associated optimal and predicted epitopes plotted on the recombinant virus from 6 
MPI of CAPRISA individual CAP256. The blue dotted lines indicate optimal epitopes with putative escape and the 
purple dotted lines indicate optimal epitopes with putative reversion. The pink dotted lines indicate predicted 
















3.3.7 CTL Data for CAP256 
 
We compared our finding to predicted peptides responses based on deconvoluted pool analysis 
(Table 3.5)(data provided by C. Gray and Mandla Mlotshwa, NICD).   
Table 3.5: CTL Responses in Gene Regions containing HLA restricted epitopes prior to, at and after Superinfection 
 
The IFN-gamma Elispot responses over time (Table 3.5) showed that prior to superinfection 
there was a narrow response, with only Env, Nef and Pol recognised out of the gene regions 
containing HLA restricted epitopes.  There was a boost of both magnitude and breadth of 
responses with all of the proteins recognised at the time of superinfection. This increased 
breadth was partially sustained after superinfection and at the time at which the recombinant is 
dominant there are several genes recognised. However envelope, to which there had previously 
been substantial responses, now had much lower responses which may have been a result of the 
two escape mutations carried by the superinfecting virus. In addition Nef had gained in the 
number of responses which may have been due to its return to the wild type sequence which 
generated a greater number of responses. Thus it would seem that these responses are 




















In this study we found evidence in CAP256 that genetic distance may play a role in enabling 
superinfection to occur presumably through escape from the immune response. For this 
individual there were also significant differences in epitope coverage between the initial and 
superinfecting viruses in several proteins. These differences may have contributed to the lack of 
recognition of the superinfecting virus by the immune response triggered by the first infection. 
To examine this further HLA restricted epitopes were studied for differences in sequence 
associated with escape. Several epitopes within the superinfecting virus were found to contain 
escape mutations. Finally a recombinant virus in CAP256 was studied; we found that the pattern 
of recombination in this virus appeared to be moulded by host immune selection as the 
recombinant was composed predominantly of the superinfecting virus which carried several 
escape mutations. The Elispot responses over time were supportive of this proposal as several 
of the responses to previously immunodominant epitopes were diminished at 6 months post 
infection when the recombinant virus was dominant. 
However, genetic distance does not play such a large role in every case of superinfection as this 
was not seen in CAP281. For this individual the genetic distance between the superinfecting 
virus and the primary infecting virus was as great as that of other circulating viruses. With 
respect to epitope coverage by the primary infecting virus, the coverage was significantly better 
in several proteins within the superinfecting virus than in other circulating viruses. The lower 
genetic distance between the initial and superinfecting viruses may have allowed the immune 
response to have better immune control over the superinfecting virus. When HLA restricted 
epitopes were examined a similar result to CAP256 was seen in CAP281, with several escape 
















have prevented the superinfecting virus from being detected by the host immune response 
prior to superinfection and thus allowed superinfection to occur. There was no CTL or antibody 
data available for CAP281. 
The genetic distance between the initial and superinfecting viruses had been previously 
suggested to influence the occurrence of superinfection with more genetically distinct viruses 
being more likely to re-infect an individual (70). On examining the genetic distance between the 
initial and superinfecting viruses in CAP256 it was discovered that in both Gag and Pol the 
superinfecting virus was more genetically distinct from the initial virus than other circulating 
CAPRISA sequences. Responses targeted against Gag have been previously shown to be involved 
with immune control of infection (58) and for individual CAP256 the Gag region was found to 
have one of the lowest percentages of epitope coverage with less than 40% of the initial virus 
matched the superinfecting virus. In addition when the coverage within HLA associated 
epitopes was studied the overall coverage of the superinfecting viruses by the primary infecting 
viruses in CAP256 was found to be significantly different to that of the other CAPRISA 
sequences. This suggests that the epitopes to which immune responses were directed towards 
were less likely to be recognized in the superinfecting virus than those of other phylogenetically 
unrelated viruses. These results are similar to those reported by Yang et al. where 
superinfection of an individual was associated with a CTL response which was primarily 
targeted at the initial virus and was thus unable to recognize the second virus. Their study 
found that the superinfecting virus had changes in the amino acid sequence of the epitopes 
targeted by the CTL response; they proposed that these sequence changes may have resulted in 
a lack of recognition of these epitopes (125). 
In individual CAP281, the genetic distance and epitope coverage between the initial and 
superinfecting strains was not as substantial as with CAP256. The regions in which the genetic 
distance was the lowest was Gag and Pol with the greatest distance observed in Envelope. These 
















primary infecting virus recognising the superinfecting virus was the same as for any of the other 
CAPRISA sequences. 
We examined the HLA associated epitopes to determine whether the superinfecting virus 
contained any mutations which may have prevented CTL recognition. Both superinfected 
individuals, CAP256 and CAP281, contained amino acid substitutions which were identified as 
potential escape mutations in several epitopes. Almost one third of the HLA associated epitopes 
in these individuals had changes in sequence which may have resulted in a lack of recognition of 
this virus. However, there was also a substantial amount of cross recognition between the initial 
and superinfecting virus within HLA associated epitopes. More than half of the HLA associated 
epitopes in CAP256 and just under half in CAP281 were conserved between the initial and 
superinfecting viruses. Thus while the superinfecting viruses in both individuals carried 
mutations which have prevented recognition, there was also potential to cross-recognition of 
the superinfecting strains. Altfield et al. also described a case of superinfection where there 
were epitopes and responses which were conserved between the two viruses. However, as was 
the case with this our study these epitopes were not sufficient to generate an immune response 
which was cross protective (4).  
A previous study had reported a case of superinfection followed by recombination which had 
resulted in loss of immune control through transmission of escape mutations from the 
superinfecting strain (102). Similarly in CAPRISA individual CAP256 the recombinant virus at 6 
months contained regions from both the primary and the superinfecting virus associated with 
escape.   Superinfection thus provided the virus with the opportunity to rapidly escape host 
immune responses through recombination resulting in the generation of a virus harbouring an 
array of both CTL and antibody and CTL escape mutations. These results illustrate the role of 
adaptive CD8 T cell responses and antibody selective pressure in molding viral genetic changes 
















resulting loss of recognition after recombination may have resulted in the observed acceleration 
of disease progression. 
To further evaluate the role of pre-existing immunity to protection from superinfection, we had 
available interferon-gamma Elispot data (C. Gray and M. Mlotshwa, NICD) and autologous 
neutralizing responses (P. Moore, NICD) from CAP256.  This individual was superinfected 
between three and four months post primary infection.  At this time there were no autologous 
neutralizing responses. However, after superinfection a neutralising antibody response began to 
develop (titres of approximately 62.5) which were directed predominantly against the 
superinfecting virus but which also exhibited some cross neutralisation of the primary infecting 
virus. There were CTL responses totalling 5200 SFU/106 PBMCs prior to superinfection 
compared to 8080 SFU/106 PBMCs after superinfection. Thus despite strong immune responses 
following superinfection the individual was still unable to control both viruses.  
 
Figure 3.17 CAP256 Natural History of Infection. Disease progression profile for CAP256 showing their viral load 
(blue), CD4 cell count (red) and CTL responses (green) over time. The red dotted line indicates the occurrence of 
















This chapter examined the genetic distance and epitope coverage between the initial and 
superinfecting viruses in two superinfected individuals. For one of these individuals (CAP256) 
the genetic distance between the initial and superinfecting virus was greater than the currently 
circulating viruses, particularly in gag and pol. Genetic distance may play a role in 
superinfection by preventing the host immune response from recognising the second virus. 
Support for this was provided by the epitope coverage across the genome which was 
significantly different to that of other CAPRISA sequences particularly in Gag, Vpr and Vpu. In 
addition the superinfecting virus was found to contain CTL escape mutations in several HLA 
restricted epitopes which may have contributed to the lack of recognition by the host immune 
responses. The host immune response also plays a role in shaping viral evolution with patterns 
of recombination appearing to be driven by the selection of escape mutations enabling the virus 
to rapidly escape immune pressure. This lack of immune recognition due to genetic differences 
between the initial and superinfecting viruses, together with rapid immune escape through 
recombination, may also have contributed to the inability of CAP256 to control both viruses and 
subsequently resulted in faster disease progression.  CAP281 however showed a different 
pattern whereby there was a much lower DNA distance observed between the initial and 
superinfecting virus, as well as better epitope coverage which may have allowed host immune 
responses to control both primary and superinfecting virus. Futher research, with increased 
numbers, is required to definitively determine the role of different host and viral factors are in 






















Chapter 4: Summary and Conclusions 
 
Vaccine strategies rely on the principle that pre-existing immunity to the pathogen will block 
infection or prevent disease. However, in HIV infection it is now established that individuals 
who are HIV positive are at risk of re-infection if exposed to another strain of HIV.   Elucidation 
of the mechanism of protection from superinfection will provide important insights into the 
correlates of immune protection that an effective HIV vaccine would need to elicit.   
The aim of this study was to determine the frequency and timing with which HIV superinfection 
was occurring within a cohort of high risk women from Kwa-Zulu Natal, South Africa. In 
addition we wanted to characterize the genome of the superinfecting viruses to determine 
whether the genetic distance between the initial and superinfecting viruses, and thus 
presumably the loss of immune cross-recognition, may have allowed superinfection to occur.  
Most previous studies have examined one or two regions of the HIV-1 genome of the 
superinfecting virus, this study looked at the entire HIV-1 genome to gain insight into the 
genetic diversity, patterns of recombination and immune escape. 
The incidence of HIV-1 superinfection over the first year of infection was 10% per person year 
(2/19) which was similar to the reported incidence of primary infection in the cohort at 7.2% 
per 100 person year (117).  This suggests that it is occurring as frequently as primary infection, 
although larger numbers are required to determine the significance.  
It had been previously proposed that the genetic distance between the initial and superinfecting 
viruses may result in lack of recognition of the second virus by the host immune system thereby 
allowing re-infection. To determine if there were significant differences in sequence between 
the initial and superinfecting viruses the genetic distance across the genome between the two 
viruses was determined in two of the superinfected individuals. It was discovered that in one 
individual (CAP256) there were considerable differences in sequence between the initial and 
















between the primary and superinfecting viruses in CAP281 and for this individual the greatest 
distance was observed in envelope.   
These differences in the CAP256 sequences were reflected in the 9-mer coverage of the 
superinfecting virus by the initial virus where coverage was found to be significantly lower in 
Gag, Vpu and Vpr in the superinfecting virus compared to other circulating CAPRISA viruses.  
Similar to the genetic distance results, for CAP281 the coverage was found to be significantly 
better in Gag, Vpu and Vpr than that of other CAPRISA sequences.   
HLA associated epitopes were then examined in both the superinfecting and initial viruses to 
determine whether sequence changes may have prevented CTL recognition. Several of the HLA 
associated epitopes in the superinfecting viruses of both CAP256 and CAP281 contained amino 
acid differences associated with escape. Approximately one third of the HLA associated epitopes 
in both individuals had potential escape mutations which may have prevented CTL recognition 
however the sequence in more than half of the HLA associated epitopes was conserved between 
the initial and superinfecting viruses. These results suggest that substantial cross-reactive 
immune responses may be required to protect against re-infection.  
We were able to track recombination patterns following superinfection for CAP256.  We found 
that recombination facilitated immune escape and the recombinant virus at six months was 
predominantly composed of the superinfecting virus.  The recombinant virus had gained several 
escape mutations from the superinfecting virus, however had retained regions of the genome of 
primary infection where the initial virus had already escaped CTL responses.  Thus 
superinfection within this individual allowed the virus to rapidly escape host immune responses 
through recombination, as had been previously found by Streeck et al., and this may have 
contributed to an accelerated disease progression(102). 
The three superinfected individuals differed in their disease progression profiles: CAP256 was 
















and CAP281 were effectively controlling their viral loads before and after superinfection. On 
studying their HLA alleles it was found that CAP256 presented the B*5802 HLA which was 
associated with high viral loads and faster disease progression which may explain the absence 
of control. CAP281 was found to present the HLA alleles B*4201 and B*4403 both of which are 
associated with low viral loads and higher CD4 cell counts which may account for the effective 
control of her viremia. No HLA data was available for CAP237 at the time of this study. The 
timing of the superinfection may also have played a role in disease outcome with both CAP237 
and CAP256 superinfected within four months of initial infection when host immune responses 
were relatively immature and CAP281 was superinfected at close to one year post infection 
when most immune responses are developed. In addition the genetic distance between the 
initial and superinfecting viruses in CAP256 was far more pronounced than that of CAP281. This 
genetic distance may mean that in the case of CAP256 once the second virus was established 
host immune responses may have been unable to recognise this virus and thus been unable to 
control viral replication contributing to the loss of control seen in this individual. In the case of 
CAP281 the DNA distance is far less which may mean that once the individual had been infected 
by the superinfecting virus the immune responses were able to more rapidly gain control of the 
replication of this virus resulting in the steady control seen in this individual.  
In conclusion this study has found that superinfection is occurring frequently with an incidence 
similar to that of initial infection. The occurrence of superinfection and the resulting 
recombination enables rapid evolution of the virus. The genetic distance between the primary 
and superinfecting viruses in some cases may play a role in enabling superinfection to occur as 
more distantly related viruses are not easily recognised by the established immune responses 
which is thus unable to prevent infection. Once infected the genetic distance may also play a role 
in how rapidly control of the viral replication of the superinfecting virus is achieved. This study 
also suggests that similar to single infection, cytotoxic T cell responses play an important role in 
















control their second viruses more effectively. Thus it would seem that the degree of cross 
recognition of the CTL responses, together with the maturity of the immune response, may be 


































Appendix A: Detailed summary of individuals who were screened for the occurrence of 
superinfection, including viral loads and CD4+ counts at twelve months post infection 
 
Appendix A1: Viral Loads and CD4+ Cell Counts at 12 months post infection for the 20 
individuals screened for superinfection 
PID Viral Load (copies/ml) Log10 Viral Load  CD4+  Cell Count (cells/ul) 
CAP30 57400 4.76 574 
CAP61 <400 2.60 308 
CAP63 214000 5.33 235 
CAP65 71300 4.85 241 
CAP69 1230000 6.09 202 
CAP129 145000 5.16 634 
CAP174 60700 4.78 363 
CAP177 18000 4.26 381 
CAP206 315000 5.50 337 
CAP210 189000 5.28 288 
CAP222 448 2.65 654 
CAP228 1520 3.18 642 
CAP237 11900 4.08 339 
CAP239 166000 5.22 1016 
CAP244 14500 4.16 303 
CAP255 18200 4.26 397 
CAP256 178000 5.25 291 
CAP257 8260 3.92 634 
CAP258 136000 5.13 233 
CAP281 5220 3.72 970 
























Appendix A2: Detailed Summary of Results of Each Individual Screened including the DNA 




HMA Result  
(Heteroduplex +/ 0) 
DNA Distance 
CAP30 
Enrolment 10200 0 0 
3 MPI 616000 0 0.009 
6 MPI 136000 0 0.015 
12 MPI 57400 0 0.0369 
Mixed NA 0 NA 
CAP61 
Enrolment 610 0 0 
3 MPI 4380 + 0 
6 MPI 7640 0 0 
12 MPI <400 0 0.0051 
Mixed NA + NA 
CAP63 
Enrolment 277000 NA 0 
3 MPI 215000 NA 0.0025 
6 MPI 186000 NA 0.0025 
12 MPI 214000 NA NA 
CAP65 
Enrolment 90800 0 0 
3 MPI 33600 0 0.0536 
12 MPI 71300 0 0.0026 
Mixed NA 0 NA 
CAP69 
Enrolment 5510000 0 0 
3 MPI 1890000 0 0.0646 
6 MPI 638000 + 0.0297 
12 MPI 1230000 0 0.0242 
Mixed NA 0 NA 
CAP129 
Enrolment 55900 0 0 
3 MPI 20600 0 0.0026 
6 MPI 62600 0 0.0079 
12 MPI 145000 0 0.0132 
Mixed NA 0 NA 
CAP174 
Enrolment 474000 0 0 
3 MPI 55900 0 0.0026 
6 MPI 28100 0 0.0053 
12 MPI 60700 0 0.0053 





















HMA Result  
(Heteroduplex +/ 0) 
DNA Distance 
CAP177 
Enrolment 698000 0 0 
3 MPI 60200 0 0.0052 
6 MPI 32300 0 0.0026 
12 MPI 18000 NA 0.0261 
Mixed NA + NA 
CAP206 
Enrolment 368000 0 0 
3 MPI 113000 0 0 
6 MPI 156000 0 0.0026 
12 MPI 315000 0 0.0026 
Mixed NA 0 NA 
CAP210 
Enrolment 127000 0 0 
3 MPI 50100 0 0.0161 
6 MPI 15700 0 NA 
12 MPI 189000 0 0.0026 
Mixed NA 0 NA 
CAP222 
Enrolment 15800 + 0 
3 MPI 5770 0 0.0365 
6 MPI 2170 0 0.051 
12 MPI 448 NA NA 




Enrolment 3840 0 0 
3 MPI 1330 0 0 
6 MPI 817 0 0 
12 MPI 1520 0 0.0079 
Mixed NA + NA 
CAP237 
Enrolment 7950 0 0 
3 MPI 15400 + 0.1107 
6 MPI 9960 0 0.1111 
12 MPI 11900 NA 0.1139 
Mixed NA + NA 
CAP239 
Enrolment 95800 NA 0 
3 MPI 23900 NA 0 
6 MPI 224000 NA 0.0026 
12 MPI 166000 NA 0.0077 
CAP244 
Enrolment 19200 0 0 
3 MPI 48900 0 0.0508 
6 MPI 54300 0 0.0333 
12 MPI 15100 0 0.0193 




















HMA Result  
(Heteroduplex +/ 0) 
DNA Distance 
CAP255 
Enrolment 196000 0 0 
3 MPI 96800 0 0.0026 
6 MPI 49200 0 0.0128 
12 MPI 74500 NA 0.018 
Mixed NA + NA 
CAP256 
Enrolment 56500 0 0 
3 MPI 51600 + 0 
6 MPI 2390000 + 0.0724 
12 MPI 178000 0 0.0725 
Mixed NA + NA 
CAP257 
Enrolment 276000 0 0 
3 MPI 173000 0 0 
6 MPI 16900 0 0.0081 
12 MPI 8260 0 NA 
Mixed NA 0 NA 
CAP258 
Enrolment 735000 0 0 
3 MPI 268000 0 0 
6 MPI 228000 0 0.0026 
12 MPI 136000 0 0.0026 
Mixed NA 0 NA 
CAP281 
Enrolment 4060 NA 0 
3 MPI <400 NA 0.0027 
6 MPI 1230 NA 0.0054 


























Appendix B: Standard Molecular Biology Techniques 
 
Appendix B1: Manual Extraction of Viral RNA 
For amplification of the whole HIV-1 genome the RNA was extracted from plasma using the 
QIAamp® Viral RNA Mini Kit (Qiagen, Valencia CA). As instructed by the kit 800ul of AVL buffer, 
which contained carrier RNA, was added to a 200ul sample of plasma in a 2ml micro-centrifuge 
tube. The tube was mixed for 15 seconds by pulse vortexing and then incubated at room 
temperature for 10 minutes. Any remaining droplets on the lid of the tube were removed by a 
brief centrifugation after which 800ul of ethanol (96-100%) was added, once again the tube was 
mixed by pulse vortexing for 15 seconds and centrifuged to remove drops from the lid. 630ul of 
this solution was then carefully applied to a QIAamp spin column which was placed in a 2ml 
collection tube. The column was then centrifuged at 6000x g (8000rpm) for 1 minute, the 
collection tube containing the filtrate was then discarded and the spin column placed in a clean 
2ml collection tube. Once more 630ul of the sample was applied to the spin column which was 
then centrifuged at 6000 x g for 1 minute.  This step was repeated until all of the solution had 
been passed through the column. The spin column was then placed in a clean collection tube 
and 500ul of buffer AW1 was added to the column. The tube was centrifuged at 6000x g for 1 
minute, the collection tube was then discarded and the spin column placed in a clean one. 500ul 
of buffer AW2 was added to the column and was centrifuged at 20 000x g (14 000rpm) for 3 
minutes. To ensure there was no remaining A2 buffer on the column it was placed in a clean 2ml 
collection tube and centrifuged at full speed for 1 minute. To elute the RNA the spin column was 
placed in a clean 1.5ml micro-centrifuge tube and 50ul of buffer AVE was carefully applied to 
the column. The column was left to stand at room temperature for at least 1 minute and was 
then centrifuged at 6000x g for 1 minute. The eluted RNA was then either used directly or 

















Appendix B2: PCR Product Purification 
To prepare amplified whole genome PCR products for sequencing the Zymo DNA Clean and 
Concentrator 5 kit (Zymo Research Corporation, Orange CA) was used.  According to the 
manufacturer’s instructions, 600ul of DNA binding buffer was added to 120ul of PCR product in 
a clean 1.5ml micro-centrifuge tube. The contents of the tube were mixed briefly by vortexing 
and then transferred to a Zymo-Spin Column in a collection tube. The column was centrifuged at 
≥ 10 000x g for 30 seconds after which the flow through was discarded and 200ul of wash 
buffer was added to the column. The tube was again centrifuged at ≥ 10 000x g for 30 seconds. 
This wash step was then repeated. To elute the purified PCR product 60ul of distilled water was 
then added directly to the column matrix; the column was then placed in a clean 1.5ml micro-
centrifuge tube and left at room temperature for at least one minute. The column was then 
centrifuged at ≥ 10 000x g for 30 seconds to elute the PCR product. The PCR product was now 

















Appendix C: Standard Buffers and Solutions 
Appendix C1: 10X TBE (Tris-Boric acid EDTA) Buffer 
108g Tris-HCl, 55g Boric acid, 20ml EDTA, made up to one litre with distilled water. 
Appendix C2: 50X TAE (Tris-Acetic acid EDTA) Buffer 
242g Tris Base, 57.1ml Glacial Acetic Acid, 20ml EDTA, made up to one litre with distilled water. 
Appendix C3: 6X Agarose Gel Electrophoresis Loading Dye 
0.25% bromophenol blue, 0.25% xylene cyanol FF 30% glycerol (In deionised water) with 1ul of 
Gel Red added per 10ml loading dye 
Appendix C4: 10X HMA Annealing Buffer 
1000mM NaCl, 100mM Tris-HCl, 20mM EDTA 
Appendix C5: 1X Electrophoresis Buffer 
100ml Buffer in 900 ml of distilled water to make up 1 litre (Diluted from either 10X TBE buffer 
or 10X TAE buffer). 
Appendix C6: 1% Agarose gel 
1% Agarose in either TBE or TAE Buffer 
Appendix C7: 5% Non-Denaturing Polyacrylamide Gel 
A 50 ml gel is prepared using 8.3ml acrylamide, 5ml of 10X TBE and 36.7ml distilled water. The 




















Appendix D: Change in HLA associated CTL epitopes of CAPRISA individual CAP256 
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Appendix E: Change in HLA associated CTL epitopes of CAPRISA individual CAP281 
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13R2C2 5' -GGCAAATATTGGAGTGTTATATGG 2712-2735 Reverse 
2U5C 5’-GGCCGCGGATCCAGTAGTGTGTGCCCGTCTGTTGTGTGACT 540-580 Forward 
5R3C 5' -CATTGCTCGTCCTACCCCCTGCCAC 7502-7526 Reverse 
E230 5' -AATATTCATAATGATAGTAGGAGG 8276-8296 Forward 
EF00 5' -GGGAAAGAGCAGAAGACAGTGGCAATGA  6204-6228 Forward 
EF110 5' -CTGTTAAATGGTAGCCTAGCAGAA 7005-7025 Forward 
EF15 5' -CTTGCTCTCCACCTTCTTCTTC 8424-8442 Reverse 
EF55 5' -GCCCCAGACCGTGAGTTGCAACATATG 7914-7937 Reverse 
ENVCR 5' -TTATATAATTCACTTCTCCAAT 7657-7678 Reverse 
For9 5' -AAAATTAGCAGGAAGATGGCCAGT 4549-4572 Forward 
G00 5' -GACTAGCGGAGGCTAGAAG 767-782 Forward 
G35 5' -CATGCTGTCATCATTTCTTCTA 1817-1835 Reverse 
GF80 5' -AGAGAACCAAGGGGAAGTGA 1477-1493 Forward 
GF85 5' -TGCACTATAGGATAATTTTG 1177-1193 Reverse 
H1P202 5' -CTAATACTGTATCATCTGCTCCTGT 2328-2352 Reverse 
P10 5' -TACTCTGGAAAGGTGAAGG 5199-5214 Reverse 
Rev12 5' -AGAGATCCTACCTTGTTATGTCCT 5488-5465 Reverse 
SQ10FC 5' -GGAGCCAGTAGATCCTAACCTAGAG  5833-5857 Forward 
SQ11RC3 5' -TTTAGGAGTCTTTCCCCATATTACTAT 3687-3713 Reverse 
SQ15FC 5' -GAGAGCGGTGGAACTTCTGG 8561-8580 Forward 
SQ16F 5' -CCACACACAAGGCTACTTCC 56-75 Forward 
SQ3R2C 5' -GCTATGGTATCAAGCAGACTAATAGCACTC 8651-8680 Reverse 
SQ4F 5' -ACAGGCTAATTTTTTAGGGA 2076-2095 Forward 
SQ5F 5' -AAACAATGGCCATTAACAGAAGAGA  2613-2637 Forward 
SQ6.5FC 5' -GCAGAGTTAGAATTAGCAGAGAACAG 3444-3469 Forward 
SQ8R 5' -CTCCGCTTCTTCCTGCCATAGGAGAT 5963-5988 Reverse 
SQ8RC 5' -TTCTACTACTCCCTGACTTTGGGGAT 4660-4685 Reverse 
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